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Abstract 
The healthcare system is facing a serious problem: the emergence of antimicrobial drug 
resistance. However, antimicrobial drug discovery and development has decelerated 
considerably throughout the past decades, creating an urgent need for the development of 
new strategies for antibiotic discovery. Streptomyces are the native producers of 
approximately 75% of the antibacterial drugs in clinical use and it is believed that we are only 
taking advantage of a small part of their production potential.  
In this work, we performed an in silico genome mining approach combined with genetic 
engineering, for the development of novel hit compounds that will ultimately feed the drug 
discovery pipeline. 
Genome mining analysis of S. natalensis ATCC 27448 unveiled 29 biosynthetic gene 
clusters coding for unknown specialized products. Six of these were submitted for an in silico 
and transcription analysis. Three predicted positive cluster situated regulators (CSRs), located 
within three different clusters and that showed no expression under laboratory conditions 
were selected for overexpression. RT-PCR analysis of S. natalensis strains overexpressing the 
CSR encoding genes SNA01173, SNA01239 and SNA06246 did not show up-regulation of 
structural genes at the analysed time point. Comparative metabolic profiling assays by 
bioassays and HPLC revealed different production patterns which suggest that novel 
biologically active compounds might being produced. Such products may further feed the drug 
discovery pipeline. Finally, overexpression of SNA01239 and SNA01173 also significantly 
altered pimaricin yield. 
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You can't put a limit on anything. The more you dream, the farther you get. 
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1.1 The need for novel compounds 
Antibiotics are agents that, due to their ability to kill microorganisms or suppressing 
their growth, have been widely used for the treatment of infectious diseases. However, the 
improper or unsuitable use of these drugs together with a poor prevention and control of 
infectious diseases, gives rise to the phenomenon known as antimicrobial resistance (AMR). 
Infections caused by resistant microorganisms often fail to respond to conventional 
treatment, resulting in prolonged illness, greater risk of death and higher costs. Each year in 
the European Union more than 25 000 people die as a direct result of the antibiotic resistant 
bacteria and is estimated economical loses of 1.5 billion euros (European Centre for Disease 
Prevention and Control, 2013). In fact, according to the World Health Organization (WHO), the 
world is heading towards a post-antibiotic era in which common infections and minor injuries, 
treatable for decades, can kill again. 
It should be noted that AMR is a not a novel problem. It has been present in society over 
the last decades and continues to increase. Moreover, multi-drug resistant Gram-negative 
bacteria such as Escherichia coli, Klebsiella pneumonia, Acinetobacter baumannii and 
Pseudomonas aeruginosa have been red-flagged as antimicrobial priority targets (European 
Centre for Disease Prevention and Control, 2009, 2013).  
Therefore, there is a political and social demand to find a solution for antimicrobial 
resistance. Besides imposing preventive measures, such as the prudent use of antibiotics, the 
development of new antimicrobials to control antibiotic-resistant bacteria is needed. 
Antimicrobial drug discovery and development has slowed down significantly during the 
last decades (Watve et al., 2001) (Fig. 1). Only a handful of antibiotics were developed and 
have hit the market in recent decades. The low profitability of antibiotics’ market from the 
point of view of pharmaceutical industry (these drugs are only taken for a short time and only 
when a patient suffers specific infections) has contributed for the lack of investment on the 
development of new antibiotics. However the need to fight AMR sets antibacterial drugs as a 
market of billions of dollars (Devasahayam et al., 2010). Moreover, the FDA and its European 
counterpart, EMA, are now actively committed in encouraging the pharmaceutical industry on 
developing new antimicrobials and in streamlining the validation of those drugs (Food and 
Drug Administration, 2011). 
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Figure 1 – Logistic model reflecting the trend of antimicrobial compounds discoveries per year, from 1947 to 1997 
[Adapted from Watve, et al., 2001]. 
1.2 Streptomyces and specialized metabolites 
Streptomyces, the largest genus of the Actinobacteria phylum, are Gram-positive, 
filamentous, obligated aerobes, soil-dwelling bacteria that present a high G+C content in the 
genome (Chater and Chandra, 2006). Their life cycle begins with the germination of a spore 
that leads to the formation of the vegetative mycelium which, after a morphological 
differentiation, gives rise to the emergence of aerial hyphae (Hardisson et al., 1978). New 
spores are originated once the aerial hyphae are divided into unigenomic compartments by 
the septation of the aerial mycelium (Fig. 2).  
 
Figure 2 – The life cycle of Streptomyces spp. [Adapted from Flardh and Buttner, 2009]. 
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Over the years, Streptomyces bacteria have attracted the interest of the scientific 
community due to their ability to produce a wide range of secondary metabolites (a.k.a. as 
specialized metabolites) of clinical, agricultural and biotechnological value. Nearly 75% of the 
antibacterial drugs in clinical use are, or are derived from, natural products synthesized by 
Streptomyces or other closely related actinomycetes species (Berdy, 2005). Additionally, 
Streptomyces also produce antifungal (amphotericin), immunosuppressive (e.g. rapamycin and 
FK506), neuroprotectant (e.g. meridamycin) and anticancer compounds (e.g. doxorubicin and 
epothilone), among others. About 7 000 secondary bioactive metabolites have already been 
isolated from Streptomyces cultures (Berdy, 2005). However, it is estimated that more than 
100 000 new bioactive compounds are still waiting to be discovered, which underlines the 
tremendous unclaimed potential of these bacteria (Watve et al., 2001). Altogether, these facts 
highlight Streptomyces as a very promising and powerful source of compounds that could be 
used to fight antibiotic resistance. 
Secondary metabolites are considered non-essential for the development and survival of 
microorganisms but there is no doubt that they play an important ecological role in their 
ability to adapt to environmental changes. The biosynthesis of these compounds generally 
occurs in a growth-dependent manner and is regulated by environmental signals.  
Current developments in DNA sequencing technologies have made genome sequencing 
faster, cheaper and more efficient. By October 2014 so far, 19 Streptomyces genomes have 
been completely sequenced and annotated and 158 more are available in scaffolds at the NCBI 
database (http://www.ncbi.nlm.nih.gov/genome/). Streptomyces spp. present large linear 
chromosomes (approximately 8–10 Mb) with over 20 putative secondary metabolite 
biosynthetic gene clusters per strain on average. The secondary metabolism diversity of these 
bacteria is reflected on the structural diversity of the proteins that govern the biosynthesis of 
polyketides, peptides, bacteriocins, terpenoids, aminoglycosides, and other natural products 
(Staunton and Weissman, 2001, Marahiel and Essen, 2009, Moore, 2008). Nonetheless, only a 
small fraction of them is expressed under laboratory controlled conditions. These biosynthetic 
clusters with reduced or no expression are known as silent or cryptic clusters and their 
activation is an auspicious strategy to produce novel bioactive compounds with the potential 
to revolutionize drug discovery pipelines. 
1.3 Genome mining 
 Recent advances in DNA sequencing techniques have led to a relatively easy and 
inexpensive access to large numbers of biosynthetic gene clusters via in silico genome mining. 
The identification of the gene clusters is facilitated, firstly, by the fact that the resulting 
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enzymes can be categorised into a small set of families (e.g. terpene cyclases, NRPS, PKS) and, 
secondly, by the characteristic patterns shared by each protein family at the protein level, 
which is reflected at the genomic level. These two facts, together with the tendency of 
biosynthetic genes to be co-localized in the genome and organized in clusters, provide the 
basis for homology-driven genome mining, where conserved protein motifs and consensus 
sequences are used to identify the loci of putative biosynthetic clusters (Gross, 2007, Nett et 
al., 2009).  
Currently there are several available bioinformatics tools for the in silico analysis of 
specialized metabolite biosynthetic gene clusters. These softwares differ from each other on 
their usability, which, in turn, depends on the following factors: (1) the quality of the sequence 
data, the user’s needs, and the user computer proficiency; (2) the capability of performing 
other functions such as predicting substrate specificity of polymerization enzymes or 
generating putative 3D structures; and (3) the ability of detecting entire secondary metabolites 
gene clusters in microbial genomes (Fedorova et al., 2012). The only ones that can actually 
identify whole biosynthetic gene clusters, rather than individualized genes, as well as different 
types of secondary metabolites are the Secondary Metabolite Unknown Regions Finder 
(SMURF; http://jcvi.org/smurf/index.php) and the antibiotics & Secondary Metabolite Analysis 
Shell (antiSMASH; http://antismash.secondarymetabolites.org/) (Khaldi et al., 2010, Medema 
et al., 2011). Both tools incorporate and integrate multiple algorithms dedicated to more 
specific analysis, such as Cluster Sequence Analyzer (CLUSEAN), NRPSPredictor, Cluster 
Scanner (ClustScan), Structure Based Sequence Analysis of Polyketide Synthases (SBSPKS), or 
Natural Product searcher (NP.searcher). 
Finally, it should also be mentioned that what distinguishes antiSMASH from SMURF is the 
fact that the latter is specific to analyse the fungal secondary metabolites gene clusters, while 
the first was preferentially developed to examine bacterial genomes. Furthermore, antiSMASH 
has some other advantages which have turned it a standard tool to analyse the bacterial 
potential to produce specialized metabolites. Those advantages are: (1) it is comprehensive, 
rapid and has a good usability; (2) it examines neighbouring regions on the chromosome to 
predict the entire gene clusters; (3) it allows running additional analyses such as clusters of 
orthologous groups, (4) it integrates into the pipeline other prediction tools, and (5) it 
combines more functionalities than any other similar programme (Medema et al., 2011, Blin et 
al., 2013). 
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1.4 Silent clusters activation strategies 
Several different approaches for the activation of silent clusters in Streptomyces have 
already been described. Ribosome engineering is one of them. This method arose from the 
initial finding of the production of the blue-pigmented antibiotic actinorhodin by a 
Streptomyces lividans strain with a mutation on the rpsL gene, which encodes the 30S 
ribosomal subunit protein S12 (Shima et al., 1996). Later, the bacterial alarmone ppGpp was 
found to bind to RNA polymerase (RNAP) (Artsimovitch et al., 2004), leading to the production 
of antibiotics (Bibb, 2005, Ochi, 2007). This last discovery suggested that RNAP might be 
modified in order to mimic ppGpp-bound form and activate the expression of secondary 
metabolite biosynthetic gene clusters (Lai et al., 2002, Xu et al., 2002). Furthermore, studies 
with Streptomyces mauvecolor 631689, a strain with no antibacterial activity in any tested 
medium, demonstrated that when the strain was mutated on the rpoB gene, which encodes 
the RNAP β subunit, and/or on rpsL, becomes able to produce a family of antibiotics known as 
piperidamycins. The result was ascribed to the increased affinity of the mutant RNAP to the 
gene promoters (Hosaka et al., 2009). 
Another possible strategy to unlock the clusters expression is to grow bacteria under 
particular stress conditions or to vary culture conditions (Scherlach and Hertweck, 2009, 
Williams et al., 2008, Bok et al., 2009). However, this approach is largely empirical, as the 
physiological conditions responsible for the activation of the silent gene clusters are not clearly 
understood and it is often not possible to predict the complex regulatory circuits involved in 
pathway regulation (Scherlach and Hertweck, 2006). 
Communication between microorganisms is also another way to induce the expression 
of silent biosynthesis gene clusters. Its potential was already demonstrated through the 
intimate interaction between the fungus Aspergillus nidulans and Streptomyces hygroscopicus, 
which resulted in the activation of a polyketide gene cluster (Schroeckh et al., 2009), or by the 
co-culturing of Streptomyces clavuligerus with the methicillin-resistant Staphylococcus aureus, 
which gave rise to the activation of the holomycin biosynthesis by the Streptomyces strain 
(Charusanti et al., 2012). However, likewise the previous strategy, the activation of the silent 
gene clusters is not completely understood and it is hard to predict what are the pathways 
involved. 
One other approach to access the compounds uncovered behind silent clusters is to 
induce their expression in a surrogate strain (Gomez-Escribano and Bibb, 2011). This is a very 
useful approach while working with difficult-to-culture microorganisms, such as rare terrestrial 
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and marine actinomycetes (Fenical and Jensen, 2006, Baltz, 2008) or myxobacteria (Wenzel 
and Müller, 2009), especially at a large scale. 
A potential candidate for heterologous protein production is the Gram-negative 
bacterium Escherichia coli, since it is well-known and its manipulation well established (Terpe, 
2006). In fact, E. coli is the most commonly used organism for this kind of experiments. The 
expression of a cryptic terpene synthase gene of Streptomyces coelicolor in E. coli was already 
achieved and it led to the identification of a new sesquiterpene, epi-isozaene (Lin et al., 2006). 
However, the use of a different bacterial genus as a host, such as E. coli, may result in 
difficulties, namely by the existence of rare codons or an unsuited metabolic background 
(Kane, 1995, Goldman et al., 1995).  
For this reason Streptomyces avermitilis and S. coelicolor, whose genome has already 
been sequenced, have been utilized for the development of expression hosts (Komatsu et al., 
2010, Gomez-Escribano and Bibb, 2012). While bellowing to the same bacterial genus, there is 
a higher chance for these bacteria to have the required supply of primary metabolic precursors 
for a successful production of the secondary metabolites, as well as reducing agents and 
energy source, also derived from primary metabolism, such as NAD(P)+ and ATP (Komatsu et 
al., 2010). Additionally, the mentioned drawbacks, such as the existence of rare codons, should 
no longer exist. In fact, it has already been shown that S. avermitilis is able to produce 
cephamycin C (from S. clavuligerus ATCC 27064) or pladienolide (from S. platensis Mer-11107) 
in higher levels than those of the native-producing species (Komatsu et al., 2010). 
Nevertheless, despite the described advantages, some other technical challenges, such as the 
transferring of large gene clusters or reduced expression may also stand as an obstacle and 
compromise the efficacy of this approach. Therefore, new molecular tools addressing those 
issues, such as the construction of vectors for the shifting of large DNA fragments, are being 
developed (Jones et al., 2013). 
Along with heterologous expression, the recent developments on high-throughput DNA 
sequencing technologies also contributed to reinforce the cluster-situated regulators (CSRs) 
manipulation as a strategy to activate silent gene clusters. The first molecular analyses of 
secondary metabolite biosynthetic gene clusters highlighted the presence of regulatory genes, 
which often have major effects on the production levels of the related antibiotic (Liu et al., 
2013). These CSR regulators, formerly known as pathway-specific, are located within the 
biosynthetic gene cluster and its regulating activity is often limited to that biosynthetic cluster, 
although some studies have revealed that pathway-specific regulators can exert a wider effect 
on global transcription patterns (Huang et al., 2005).  
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It is a fact that CSRs can directly control the expression and activity of biosynthetic gene 
clusters. However, it should still be noted that the action of pleiotropic regulators, presenting a 
wide-range effect over cell metabolism, may also result in the modulation of the biosynthesis 
of secondary metabolites (Gust et al., 2004) (Fig. 3). For example, in S. coelicolor, the two-
component system PhoR-PhoP, besides being the major signal transduction system for 
phosphate control, it has also been associated with the negative regulation of some secondary, 
and even primary metabolic pathways (Allenby et al., 2012, Liu et al., 2013). Once 
phosphorylated by PhoR, PhoP binds to the promoter region of the target gene, influencing its 
expression. The promoter of afsS, which encodes a global activator of antibiotic production, is 
a target, and its repression affects indirectly actinorhodin and undecylprodiginine production 
in S. coelicolor (Santos-Beneit et al., 2009). The CSR encoding gene, cdaR, which regulates the 
calcium-dependent antibiotic biosynthesis in S. coelicolor, is regulated directly by PhoP 
(Allenby et al., 2012). Furthermore, PhoR-PhoP system also plays an important role in the 
regulation of nitrogen metabolism in S. coelicor, due to PhoP ability to bind to the promoter 
region of glnR. GlnR is the main nitrogen regulator and controls the expression of several 
genes involved in nitrogen metabolism. In fact the nitrogen metabolism, through a different 
two-component regulatory system AfsQ1/Q2, may also stand as another example of an 
indirect effect over CSRs. AfsQ1 has been revealed as a direct repressor of primary nitrogen 
assimilation genes and as an activator of several CSRs such as actII-ORF4, redZ, and cdaR 
(Wang et al., 2012). Moreover, AfsQ1 recognizes a moderately conserved pair of sequences 
similar to that recognized by the nitrogen regulator GlnR, leading to a competition between 
GlnR activation and AfsQ1 repression (Wang et al., 2012). 
Understanding the major role of CSRs highlights their genetic manipulation as a 
straightforward approach to activate silent gene clusters either by overexpressing activators or 
deleting repressors. In the year of 2007, Bergmann and co-workers demonstrated that the 
expression of a putative CSR encoding gene under the control of an inducible promoter causes 
the expression of a normally silent gene cluster in Aspergillus nidulans upon the addition of the 
inducer (Bergmann et al., 2007). Aspyridones, the metabolic products of that gene cluster, 
were identified by comparative metabolic profiling of the wild-type and mutant strains and 
spectroscopic analyses showed them to have novel structures (Bergmann et al., 2007). In the 
same way, the overexpression of the CSR samR0484, a LAL-family regulatory gene of 
Streptomyces ambofaciens, activated the expression of a cryptic type I PKS cluster, resulting in 
the production the stambomycins, macrolides with anti-proliferative activity against cancer 
lines (Laureti et al., 2011). Concordantly with the previous experiments, the removal of scbR2, 
a gene encoding an inhibitory protein, allowed initiating the expression of the antibacterial 
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compound abCPK, from S. coelicolor (Gottelt et al., 2010), and, thus, proving the utility of this 
approach for discovering new natural products of silent biosynthetic gene clusters that are not 
expressed in laboratory cultures (Scheffler et al., 2013). 
 
Figure 3 – The influence of the sources of carbon, nitrogen, and phosphate upon CSR expression. Solid lines 
represent direct interactions, while the dotted ones represent unknown routes (dotted lines). Arrows 
indicate activation, and bars indicate repression [Adapted from Liu et al., 2013]. 
1.5 Aim of this work 
The present work aimed to activate silent clusters in Streptomyces natalensis by 
manipulating CSR encoding genes.  
Streptomyces natalensis ATCC 27448 was used as work model. This strain was first 
isolated from a soil sample originated from South Africa (Natal province) and is the producer of 
the antifungal polyene macrolide pimaricin (commercial name natamycin, E235) widely used in 
the food industry to prevent mould contamination of cheese and other non-sterile foods. 
Additionally, S. natalensis ΔpimM, a strain that lacks pimaricin production due to the absence 
of the positive CSR PimM (Anton et al., 2007) has also been used. 
As specific objectives it was proposed (1) the in silico and (2) transcription 
characterization of six biosynthetic gene clusters detected by antiSMASH in S. natalensis 
genome; (3) the overexpression of three selected CSR; and (4) evaluate the effect of CSR 
overexpression on the transcription and metabolic profile.  
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2.1 Strains, growth conditions and plasmids 
2.1.1 Streptomyces strains 
The Streptomyces strains used in this work were Streptomyces natalensis ATCC 27448, a 
pimaricin producer, and the derivative S. natalensis 40D9-1 (ΔpimM) (Antón et al., 2007), a 
pimaricin non-producing strain.  
Sporulation was achieved in TBO medium [2% (w/v) oat flakes, 2% (w/v) tomato paste, 
2.5% (w/v) agar, pH 6.5] (Higgens et al., 1974) at 28 °C. After 8-10 days of growth, spores were 
scrapped from solid medium using a 0.025% (v/v) Triton X-100 and 30% (v/v) Glycerol solution, 
filtered with cotton and stored at -80 °C in the same solution. Spore concentration was 
determined spectrophotometrically at 600 nm using the following ratio: 0.1 units of absorption 
corresponds to 108 spores per mL (Kieser et al., 2000). 
For Streptomyces liquid cultures, 108 spores were inoculated in YEME medium without 
sucrose [0.3% (w/v) yeast extract, 0.5% (w/v) bacto peptone, 0.3% (w/v) malt extract, 5 mM 
MgCl2 and 1% (w/v) glucose] (Kieser et al., 2000) and grew in an orbital incubator shaker at 
28 °C and 220 rpm, with a ratio of medium culture volume:flask volume of 1:10. 
2.1.2 Escherichia coli strains 
Escherichia coli ET12567 was used as a donor strain in intergeneric conjugation with 
Streptomyces. This strain does not methylate DNA (dam-) (MacNeil, 1992), which helps 
circumventing the methyl-specific restriction system of Streptomyces. In addition, it harbours 
the non-transmissible plasmid pUZ8002 that contains the genes (tra genes) necessary for the 
mobilization of other vectors. Moreover, pUZ8002 also holds kanamycin and chloramphenicol 
as selection markers. E. coli DH5α was routinely used to transform and replicate plasmid DNA 
and also for bioassay experiments. 
E. coli strains were routinely grown in LB medium [1% (w/v) bacto-tryptone, 0.5% (w/v) 
yeast extract, 0.5% (w/v) NaCl] (Miller, 1972) at 37 °C. For solid LB medium 2% (w/v) agar was 
added. 
2.1.3 Test microorganisms 
The Gram-positive bacterial strains Bacillus cereus ATCC 14579, Enterococcus faecalis 
ATCC 29212 and Staphylococcus aureaus ATCC 29213 were used together with E. coli DH5α 
and Saccharomyces cerevisiae BY4741, as test organisms for bioassay experiments. These 
microorganisms were first grown O/N in submerged cultures and 1 mL was used for growth 
inhibition assays. B. cereus was grown in LB medium at 37 °C, Enterococcus faecalis and 
Staphylococcus aureaus were grown in TSB medium (Sambrook and Russel, 2001) at 37 °C and 
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Saccharomyces cerevisiae was grown in YPD medium [1% (w/v) yeast extract, 2% (w/v) bacto 
peptone, 2% (w/v) glucose] (Ausubel et al., 1992) at 26 °C. For solid TSB and YPD media 2% 
(w/v) agar was added. 
2.1.4 Plasmids 
The oriT-containing pIB139 plasmid (Wilkinson et al., 2002) was used for the expression 
of genes under the strong promoter ermE*p in Streptomyces (Paget et al., 1999). Apramycin 
stands as the selection marker for this plasmid. 
PCR amplicons were cloned in pGEM®-T Easy vector (Promega) for DNA sequencing. 
Ampicillin is the selection marker for this plasmid, together with lacZ gene that codes for the β-
galactosidase. 
2.2 DNA procedures 
2.2.1 Purification of total DNA from Streptomyces 
Purification of total DNA from Streptomyces was carried out using the MasterPure™ 
Gram Positive DNA Purification Kit (Epicentre). A sample of 1 mL of culture broth was 
harvested and washed in 1 mL of TE buffer [10 mM Tris-HCl, pH 7.5, 1 mM EDTA]. For cell lysis, 
mycelium was resuspended in 300 μL of TE Buffer containing 2 μL of Ready-Lyse Lysozyme to 
each sample and incubated at 37 °C for 1.5 h. Then, 300 μL of Lysis Solution with 2 μL 
Proteinase K were added to each sample, mixed thoroughly and incubated at 65 °C for 30 min. 
DNA cleaning and purification was achieved firstly by adding 350 μL of MPC Protein 
Precipitation Reagent and mixing vigorously by vortex. Next, 2 μL RNAse A were added and 
samples were incubated at 37 °C for 30 min. Protein precipitation was carried out by mixing 
the samples with 1 vol. of phenol-chloroform-isoamyl alcohol (25:24:1). The aqueous phase 
was recovered after centrifugation (10 min, 12100 g) to a new tube and 0.6 vol. of isopropanol 
and 0.1 vol. of 3 M sodium acetate pH 5.2 were added. Samples were centrifuged at room 
temperature (10 min, 12100 g) and the supernatant was discarded. The DNA pellet was rinsed 
with 500 μL cold ethanol 75% (v/v) and resuspended in 50 μL of H2O. 
Plasmid DNA was isolated using the GenEluteTM Plasmid Miniprep Kit (Sigma-Aldrich, 
Saint Louis, MO) following manufacturers’ instructions.  
2.2.2 Enzymatic manipulation of DNA 
For the ligation of DNA molecules a ligase isolated from the phage T4 (T4 DNA ligase) 
was used. T4 DNA ligase from Promega and Fermentas were used according to manufacturers’ 
instructions. 
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Restriction endonucleases were used to cleave DNA of specific nucleotide sequences. 
EcoRV, NdeI, BglII, AgeI, NcoI and NotI (Fermentas) were used according to the indications 
provided by the manufacturer. 
2.2.3 Transformation of E. coli strains 
E. coli DH5α transformation was performed as previously described (Sambrook and 
Russel, 2001). First, 5 µL of recombinant DNA was added to competent cells prepared by the 
rubidium chloride method and incubated on ice 45 min. Aliquots were then heat shocked at 
42 °C for 1.5 min, 1 mL of LB was added, and cells were further incubated at 37 °C. Finally, 
recombinant cells were plated on solid LB medium, supplemented with IPTG (100 μM), X-Gal 
(20 μg/mL) and ampicillin (50 µg/mL) if transformed with pGEM®-T Easy derivative plasmids, or 
with apramycin (SIGMA-Aldrich) (50 μg/mL) if transformed with pIB139 derivative plasmids. 
E. coli ET12567 [pUZ8002] was transformed by electroporation. Briefly, 1 mL of an O/N 
culture was inoculated in 10 mL of fresh LB supplemented with kanamycin (50 μg/mL), and 
chloramphenicol (25 μg/mL) and grown at 37 °C until an OD600nm of 0.8-0.9. Then, cells were 
washed twice in 10 mL of cold-ice H2O and in 5 mL of cold-ice 10% (w/v) glycerol. Cells were 
resuspended in 50 mL of 10% (w/v) glycerol and 100 ng of DNA was added. Electroporation 
was performed in a Gene Pulser® (BioRad) with an intensity of 2.5 Ω. Cells were left to recover 
at 37 °C for 1 h and plated in solid LB medium supplemented with kanamycin (50 μg/ml), 
chloramphenicol (25 μg/mL) and apramycin (50 μg/mL). 
2.2.4 Intergeneric conjugation 
A culture of the donor strain E. coli ET12567 [pUZ8002], harbouring pIB139 or 
derivatives was inoculated in LB supplemented with kanamycin (50 μg/mL), chloramphenicol 
(25 μg/mL) and apramycin (50 μg/mL), and grown overnight at 37 °C. 1 mL of this pre-culture 
was inoculated in 10 mL fresh LB supplemented with the same antibiotics and grown at 37 °C 
until an OD600nm of 0.5-0.6. Cells were washed twice with LB medium without antibiotics and 
resuspended in 25 mL of the same medium. Spores of S. natalensis or S. natalensis ΔpimM 
were used as recipients. For each strain, 108 spores were washed with 2xTY medium [1.6% 
(w/v) bacto-tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl] (Sambrook and Russel, 2001) 
and resuspended in 500 µL of the same medium. Spores were then subjected to a heat-shock 
(45 °C for 10 min). 500 µL of E. coli ET1256 [pUZ78002] cells harbouring the plasmid to be 
transferred was added to the treated spores and the mixture was incubated at 30 °C for 15 
min. The mixture was pelleted, resuspended in the residual liquid and spread on MS [2% (w/v) 
manitol, 2% (w/v) soya flour, 2% (w/v) agar %] (Hobbs et al., 1989) supplemented with 10 mM 
MgCl2. Plates were incubated at 30 °C for 16-18 h and then overlaid with 500 µL of an aqueous 
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solution containing apramycin (50 mg/mL) and nalidixic acid (25 mg/mL). Plates were 
incubated for further 10-15 days until exconjugants appeared. Exconjugants colonies were 
transferred to a new TBO plate supplemented with nalidixic acid and apramycin. For validation 
purposes, the identity of all new strains was confirmed by Southern blot hybridization and PCR. 
2.2.5 Southern blot hybridization 
The screening of the pIB139 plasmid integration into S. natalensis ATCC 27448 and S. 
natalensis 40D9-1 was made first by antibiotic resistance selection and confirmed by Southern 
blot hybridization, as previously described (Sambrook and Russel, 2001). 
Initially, DNA was digested by restriction endonucleases and the resulting fragments 
were separated by electrophoresis in a 0.8% (w/v) agarose gel. The lambda (λ) phage DNA 
digested with Hind III labelled with digoxigenin (DIG) (Roche) was used as molecular weight 
ladder. DNA was transferred from the agarose gel to a nylon membrane (Amersham) in the 
vacuum system (Bio-Rad) and following manufactures’ instructions.  
DNA probes were labelled with digoxygenin using the “DIG-High prime” (Roche) kit and 
following the protocol provided by the manufacturer. Generally, 300-500 ng of DNA template 
were used in the digoxigenin labelling procedure. Hybridization and detection were performed 
as afore described (Sambrook and Russel, 2001) and using the alkaline phosphatase substrate 
CPD-Star (Roche). 
2.3 Purification of total RNA from Streptomyces 
Total RNA purification from Streptomyces was performed using RNeasy Mini Kit (Qiagen) 
and following a protocol optimized for Streptomyces (Beites et al., 2011). Briefly, 500 µL of S. 
natelensis culture broth was collected and mixed with 1 mL of RNA Protect Bacteria Reagent 
(Quiagen), incubated for 5 min at room temperature, harvested by centrifugation (10 min, 
3600 g) and immediately stored at -80 °C. For total RNA extraction, mycelium pellets were 
resuspended in Buffer RLT with 1% (v/v) β-mercaptoethanol. Cellular disruption was achieved 
by sonication (Branson Sonifier, Model B-15) using cycles of 5 seconds, duty cycle of 50%and 
an output of 3. RNeasy Mini Spin columns were used to recover total RNA and DNA was 
removed by two serial DNase treatments, an in-column DNase I RNase-free (Qiagen), followed 
by a batch treatment using the DNA-free Kit (Ambion). The absence of genomic DNA was 
confirmed by PCR.  
RNA quantification was assessed by NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific), and its quality and integrity was evaluated in an ExperionTM Automated 
Electrophoresis System (Bio-Rad). 
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2.4 Polymerase Chain Reactions (PCR) and Reverse Transcription (RT) PCR 
DNA amplification by PCR was performed with Pfu DNA polymerase (Fermentas) or 
GoTaq Flexi DNA Polymerase (Promega) according to manufactures’ instructions. The DNA 
amplification was performed in a C1000™ Thermal Cycler (BIORAD). Used primers are listed in 
Table 1. 
The genetic identity of the PCR products used for overexpression was confirmed by 
sequencing (STAB Vida). For gene expression studies 1 µg of DNase-treated total RNA was 
transcribed with the iScript™ Select cDNA Synthesis Kit (Bio-Rad), following the manufacturer's 
instructions. To check if there was any trace of genomic DNA in the samples, a standard PCR 
reaction was performed using specific primers for S. natalensis ATCC 27448 16s rRNA gene and 
3 μl of the DNAse treated RNA sample as template. As a positive control it was used the S. 
natalensis ATCC 27448 genomic DNA. The housekeeping gene 16S rRNA was used as a positive 
internal control for both strains, while the PimM direct target pimS1 (pimaricin biosynthetic 
gene cluster) (Santos-Aberturas et al., 2011) was used as a negative control for the ΔpimM 
strains. Genomic DNA was used as control for RT-PCR reactions where transcripts were not 
detected, or detected in low levels. 
Table 1 – Primers used in this work. They are categorized according to their application: RT-PCR, gene 
overexpression or strain validation. Primers included in the strain validation category were used for 
both PCR studies and amplification of the Southern blot hybridization probes. Primers marked with (*) 
were also utilized for strains validation by PCR. Primers marked with (ϯ) were additionally used for the 
development of the probes required for Southern blot hybridization. 
Primer Sequence (5’-3’) Target Amplicon Size (bp) 
RT-PCR 
S1C1R1_AS ACCAACGACCAGGACACCCTC 
SNA00088 119 
S1C1R1_S TCGCGCAGGGAACGGAAG 
S1C1R2_AS ATGCGAACCGGCGAGGAC 
SNA00096 102 
S1C1R2_S GCTGACCCCCATGAAGCACA 
S1C1S1_AS TCAAGAGCCCCGGCCGAC 
SNA00095 104 
S1C1S1_S GTCGTTGTGGACCTCTACCGCC 
S1C2R1_AS AAGTGGACCTGGACGGCGAG 
SNA00399 118 
S1C2R1_S TGGAAGACCATCCGGACCTCT 
S1C2R2_AS GAGTGCGTCGAAGCCATGCG 
SNA00403  125 
S1C2R2_S GCCTTCGCGCCTTCGATGAA 
S1C2R3_AS GGGCCGTGATGGACGAGACC 
SNA00404 133 
S1C2R3_S CCGGAAGCGAAGGGCATGAC 
S1C2R4_AS TCATGGACGGTCTGCTGCTG 
SNA00428  152 
S1C2R4_S CTTGGGACGGTAGGGGTGGT 
S1C2R5_AS ACCTGGTCGTCTTTCTGCGC 
SNA00433 115 
S1C2R5_S TTCTCGGTGATCCACTGCTGG 
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Table 1 – Primers used in this work (continuation). 
Primer Sequence (5’-3’) Target Amplicon Size (bp) 
RT-PCR 
S1C2S1_AS GACACACCGCGACCTTCACC 
SNA00397 122 
S1C2S1_S GAAGACCACATCGACCTCCTCC 
S1C2S2_AS ACGACCGTACCGCCGACAT 
SNA00414 157 
S1C2S2_S ACGACCGGCAGCGACTTCT 
S1C3R1.2_AS AGACGCACGGCCTGCTACG 
SNA00830 117 
S1C3R1.2_S TGTAGGTCTGGACGACGATGCC 
S1C3R2.2_AS TCGTAGCCGGTCAGCAGCC 
SNA00835 141 
S1C3R2.2_S ACACCTCGACGTCCCCGTAC 
S1C3R3_AS ATTCCCAAGGGGTCGGTGA 
SNA00851 193 
S1C3R3_S GCACCACGAAAGGCAGCTT 
S1C3S1_AS CCGGCGACCTGGACTTCTACAT 
SNA00841 133 
S1C3S1_S GCGATGTTGCCGTACTCGGTC 
S1C4R1_AS*; ϯ AGAGTGCGAGGCCGTTGGG 
SNA01173 106 
S1C4R1_S ϯ AACCCGCGCGACATCTGC 
S1C4S1_AS ATGGCGCTGGGTGTCGGT 
SNA01166 115 
S1C4S1_S CGCCCGCGCCTATGACTT 
S1C5R1_AS CAGGAACTCCCGGAAGATGCC 
SNA01232 174 
S1C5R1_S AAGGTCGGCAAGGGAACGGT 
S1C5R2_AS*;ϯ CGCAGAACACTCCGACGCA 
SNA01239 102 
S1C5R2_Sϯ GGTCATGGACCGGGAGCTCT 
S1C5R3_AS ATCTCGCGGCAGTCCGGTC 
SNA01250 103 
S1C5R3_S CGTGGTGGCCCAGGAAGATG 
S1C5R4_AS ATCGACGTACGAGGCGAGCT 
SNA01254 147 
S1C5R4_S GAGCGGCACAAGCGTCATCT 
S1C5R5_AS GATCCTCGCTGAAGGTCGTCTC 
SNA01258 109 
S1C5R5_S CTCCAGGACGCCATCGACTT 
S1C5R6.2_AS GGACTGGACCCGCTCGAAGA 
SNA01256  143 
S1C5R6.2_S CCAAGGACGACCTCACCCTC 
S1C5S1_AS GGCAGCAGGTCTACGAGCGTAT 
SNA01225 117 
S1C5S1_S ACTGCCGCATCTCTGCCAGA 
S5C20R1_AS TGACCGTCCAGGGCACTGAAC 
SNA06239 108 
S5C20R1_S CTTCCGCAGCCACCCATGG 
S5C20R2_AS ACGGCGAGGCCCTGAATGTAG 
SNA06240 132 
S5C20R2_S CCCCTTGATGCTGCCCAA 
S5C20R3_AS TGAGCTGGAGGCGACTGTGCT 
SNA06245  157 
S5C20R3_S AAGGATTTCGCCGCCGGA 
S5C20R4_AS*; ϯ CTTTCCCGGCAGCGATGA 
SNA06246 157 
S5C20R4_S ϯ CCATCTGGGAAATGACGCGC 
S5C20R5_AS ACGATGCCCTTCCCGCTGA 
SNA06261 114 
S5C20R5_S CTCCGGTTTCTGTTTCTCGCG 
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Table 1 – Primers used in this work (continuation). 
Primer Sequence (5’-3’) Target Amplicon Size (bp) 
RT-PCR 
S5C20R6_AS CGGCAGCCGATGGTGAGTT 
SNA06243  192 
S5C20R6_S CCTCATCCGCGCCTACACG 
S5C20S1_AS TACTCACCATGGCTGTGCCCC 
SNA06257 160 
S5C20S1_S TGCTGTCCGTGCTGTTCCCT 
PimS1_AS CCACCTTCGGACGCAACAC 
pimS1 108 
PimS1_S TGGCTCGGCATCGGATCA 
16S_AS CTCCTCAGCGTCAGTATCG 
16s rRNA 117 
16S_S CAGGCTAGAGTTCGGTAGG 
Gene overexpression 
SNA01239_F TAGGGCATATGGACGCGATGACCCTCTAC 
SNA01239 957 
SNA01239_R AGGATATCGACTATACGTCGCGGTCGATCCG 
SNA06246_F GCGGCATATGAAGAACTCACTGCTGGTC 
SNA06246 672 
SNA06246_R CCGATATCTCAGCCGGGGAGGAGGATCTG 
SNA01173_F GGCCCATATGGTCGTCGTGGCCGAC 
SNA01173 617 
SNA01173_R GCGATATCGGTCAGTGGATGATGCCCGTACG 
Strains validation  
pIB_U_F GGCTTGCGCCCGATGCTAGT pIB139 
plasmid 
293 
pIB_U_R CCGGCTCGTATGTTGTGTGG 
2.5 Bioassay experiments 
S. natalensis strains were cultured in YEME liquid medium for 72 h, in order to ensure 
the production of secondary metabolites. 8 mL of culture broth were centrifuged twice (5 min, 
12 100 g) and 250 µL of the recovered supernatants were concentrated, until a final volume of 
40 µL, before being transferred to holes of 0.5-cm diameter cut in solid LB, TSB or YPD plates, 
and let diffuse in the media for 1 h at room temperature. Next, 1 mL of O/N cultures of test 
microorganisms was added to the plates, within 15 mL of pre-warmed LB, TDB or YPD 
supplemented with 1% (w/v) agar. Inhibition zones were measured 2 days later using a Vernier 
caliper. 
2.6 Analysis of specialized metabolites by high performance liquid 
chromatography (HPLC) 
For pimaricin quantification, 500 μL of S. natalensis culture broth was collected and 
mixed with 1 vol. of methanol. Samples were left 2 h at 30 °C with agitation in order to 
enhance the extraction of the pimaricin to the organic phase. The organic phase was recovered 
through centrifugation (5 min, 12 100 g) before HPLC analysis. Pimaricin quantification was 
performed on a Merck-Hitachi liquid chromatograph (Merck-Hitachi, Tokyo, Japan), equipped 
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with a detector L-4000, an autosampler L-7250, a pump L-7100, an L-7300 column oven and an 
interface D-7000. Chromatograms were recorded and processed on a Merck-Hitachi D-7000 
HSM PC-based chromatography data system, setting wavelength at 304 nm. Strain metabolic 
profile was performed on a Dionex UltiMate 3000 system (Thermo Fisher Scientific, Bremen, 
Germany) equipped with an UltiMate 3000 RS pump, an UltiMate 3000 RS autosampler and an 
UltiMate 3000 RS column compartment, and coupled to an Accela PDA detector. Both systems 
were filted with a SunFire™ C18 column (5 μm, 4.6 × 250 mm; Waters). Elution was performed 
with a gradient of mobile phase composed of 0.1% (v/v) trifluoroacetic acid (solvent A) and 
HPLC-grade methanol (solvent B) at a flow rate of 0.6 mL/min and according to the following 
progam (methanol concentration): 50% B, 0-3 min; 90% B, 3-12 min; 90% B, 12-22 min; down 
to 50% B, 22-26 min; 50% B, 26-30 min. Purified pimaricin (Biocam) was used as standard 
solution for the quantification of this metabolite.  
Dry weight was used to determine the specific pimaricin production. 1 mL of culture 
broth was collected and washed twice in 1mL of 0.9% (w/v) NaCl. Mycelium was pelleted by 
centrifugation (5 min, 12 100 g) and dried at 60 °C for 5 days. 
2.7 In silico analysis  
2.7.1 Prediction and analysis of secondary metabolite biosynthetic gene clusters 
Secondary metabolite gene clusters were identified in silico using the bioinformatic tool 
antiSMASH (http://antismash.secondarymetabolites.org/). Additionally, this software was also 
utilized for the prediction of the putative chemical structures of the products derived from 
PKS, NRPS or hybrid PKS-NRPS gene clusters, as well as the domain specificities of their 
biosynthetic core genes. Finally, in order to get more reliable predictions on the clusters’ genes 
function and the chemical structure of the secondary metabolite, antiSMASH results have 
been manually curated. In specific, a BLASTp analysis (www.ncbi.nlm.nih.gov/BLAST/) on every 
gene of each cluster has been performed, as well as a literature review regarding putative 
identical biosynthetic gene clusters. 
2.7.2 Internet resources 
EMBL (European Molecular Biology Laboratory, Germany): www.ebi.ac.uk/.  
BLAST: www.ncbi.nlm.nih.gov/BLAST.  
NCBI genome database: www.ncbi.nlm.nih.gov/genome/browse.  
Streptomyces genome project: http://streptomyces.org.uk/.  
S. avermitilis genome project: http://avermitilis.ls.kitasato-u.ac.jp/.  
 
Page 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Results and discussion 
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3.1 S. natalensis ATCC 27448 genome mining  
The S. natalensis ATCC 27448 genome has been recently sequenced (Mendes et al., 
unpublished results). The draft genome is distributed among 40 scaffolds and is estimated to 
have a total size of 8 653 788 bp, a G+C content of 70.63% and an estimated total of 8 318 
protein-coding genes. The S. natalensis genome was submitted to a preliminary genome 
mining analysis using antiSMASH (http://antismash.secondarymetabolites.org/) – a software 
especially developed to identify and delimit secondary metabolites biosynthetic gene cluster 
(for more detailed description see section 1.3).  
The antiSMASH analysis retrieved a total of 29 predicted biosynthetic gene clusters 
putatively involved in the production of secondary metabolites (a.k.a. specialized metabolites), 
including 8 terpenes, 3 bacteriocin-like toxins, 3 siderophores, 3 polyketides, 2 nonribosomal 
peptides, 1 oligossacharide, 1 phosphonate, 1 polyketide-siderophore-terpene hybrid and 1 
polyketide-terpene hybrid (Table 2). Based on PFAM domain probabilities 33 additional 
putative biosynthetic gene clusters were identified with no assigned category. Moreover, the 
majority of the identified secondary metabolite biosynthetic gene clusters harboured at least 
one putative cluster situated regulator (CSR). Finally it should be mentioned that the 29 
biosynthetic gene clusters may turn out to be 34 due to the classified hybrid ones (S1C2, S3C9 
and S3C14). antiSMASH defines gene clusters by locating clusters of signature gene pHMM 
hits, spaced within <10 kb mutual distance, including flanking accessory genes. Then, gene 
clusters are extended by 5, 10 or 20 kb on each side of the last signature gene pHMM hit 
(Medema et al., 2011). Consequently, gene clusters that are closely located may be merged 
and wrongly assigned as a hybrid one. 
Due to time constraints, this work has focused on six clusters (S1C1, S1C2, S1C3, S1C4, 
S1C5 and S5C20). The selection process was based on (1) the chemical family of the predicted 
metabolite, to favour chemical diversity, (2) low genetic synteny with homologous gene 
clusters, to increase the probabilities of finding a new compound and (3) the existence of 
positive CSRs. Biosynthetic gene clusters were named according to the scaffold they belong 
sequentially (e.g. S3C12 is the 12th found cluster and is located in scaffold no 3). A detailed in 
silico analysis of the selected clusters was performed based on the antiSMASH results. 
Individual BLASTp results for each gene of the selected clusters are presented in Tables A1-6 
(Appendix I). Table A7 summarizes the CSR found and their predicted role (i.e. if activators or 
repressors) based on previous studies. It should still be noted that all the proposed functions 
were foreseen according to (1) the position of the homologous hits presented by NCBI, (2) the 
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number of similar obtained homologies and (3) the core domains detected by the alignment 
search tool. 
Table 2 – S. natalensis ATCC 27448 biosynthetic gene clusters predicted by antiSMASH. Gene loci was identified with 
the SNA prefix in accordance with the genome sequencing data. 
Gene 
cluster 
Type No Scaffold: Location (bp) SNA loci 
S1C1 Terpene S1: 77463-100227  SNA00083-SNA00105 
S1C2 PKS-II-terpene S1: 370687-434883 SNA00375-SNA00437 
S1C3 PKS-III S1: 835946-878512  SNA00822-SNA00859 
S1C4 Bacteriocin S1: 1186177-1211143 SNA01156-SNA01179 
S1C5 NRPS S1: 1222359- 1330255  SNA01188-SNA01259 
S1C6 Siderophore S1: 1490934-1508777  SNA01393-SNA01404 
S2C7 Phosphonate S2: 524293-566518  SNA03120-SNA03161 
S3C8 Other S3: 1795-46346 SNA03856-SNA03898 
S3C9 Terpene-Lantipeptide-NRPS S3: 278972-346052  SNA04152-SNA04201 
S3C10 Terpene S3: 390167-411216  SNA04263-SNA04289 
S3C11 Terpene S3: 492921-516009  SNA04392-SNA04413 
S3C12 Oligosaccharide S3: 519254-572380  SNA04417-SNA04462 
S3C13 PKS-I S3: 587907-651587  SNA04479-SNA04537 
S3C14 PKS-I-Siderophore-Terpene S3: 652887-799820  SNA04539-SNA04613 
S3C15 Lantipeptide S3 985892-1012524  SNA04789-SNA04809 
S3C16 Bacteriocin S3: 1126391-1138879  SNA04917-SNA04925 
S4C17 Terpene S4: 336772-360465 SNA05344-SNA05364 
S4C18 Bacteriocin S4: 574834-586218 SNA05566-SNA05578 
S5C19 Terpene S5: 66559-91614 SNA05856-SNA05877 
S5C20 PKS-I S5: 460920-515784 SNA06231-SNA06280 
S6C21 NRPS S6: 266965-367965 SNA06673-SNA06733 
S6C22 Siderophore S6: 491157-507468 SNA06857-SNA06869 
S7C23 Other S7: 100-42269 SNA06906-SNA06955 
S7C24 Terpene S7: 435422-456849  SNA07423-SNA07440 
S8C25 Ectoine S8: 393588-404835 SNA07875-SNA07887 
S10C26 Terpene S10: 267-15488 SNA01458-SNA01477 
S10C27 Siderophore S10: 301253-310365 SNA01750-SNA01755 
S13C28 Terpene S13: 20834-44430  SNA02207-SNA02226 
S16C29 Butyrolactone S16: 433-13110  SNA02426-SNA02441 
Finally, the transcription of one selected structural gene together with CSRs encoding 
genes from the six clusters was analysed by RT-PCR nature. The large amount of structural 
genes, together with the short period of time available for this project, justifies the performed 
selection. For gene expression studies RNA samples were collected at early experimental 
phase where secondary metabolism is active. Two biological replicates were analysed. 
3.1.1 S1C1 – a putative terpene biosynthetic gene cluster 
3.1.1.1 In silico analysis 
Cluster S1C1 spanning from 682408-700166 in scaffold 1 (SNA00083-SNA00105) was 
classified by antiSMASH as responsible for the production of a terpene (Fig. 4). Terpenes (a.k.a. 
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isoprenoids) are a ubiquitous group of molecules biosynthetically derived from units of 
isoprene precursor units (C5H8). Currently, over 55 000 of terpenes have been isolated and are 
present in our daily life, such as components of fragrances, hormones and medicines, among 
other products (Nicolaou & Montagnon, 2008; Chen & Baran, 2009). 
In Streptomyces, terpenes biosynthesis can occur via two independent non-homologous 
metabolic pathways: the methylerythritol phosphate (MEP) pathway and the 
mevalonate (MVA) pathway (Dairi, 2005). Both pathways converge in the formation of 
isopentenyl pyrophosphate (IPP), from the condensation of a pyruvate and a glyceraldehyde-3-
phosphate (G3P) (MEP pathway) or from the condensation of acetyl-CoA and acetoacetyl-CoA 
(MVA pathway) (Fig. 5). 
 
Figure 4 – Schematic representation of cluster S1C1. Brown arrows represent putative structural genes, which might 
be involved in the biosynthesis of the end terpene (SNA00094, methyltransferase; SNA00095, terpene 
synthase metal-binding domain-containing protein; SNA00100, AMP-dependent synthase SNA00101, 
phosphopantetheine-binding protein; SNA00102, decarboxylase). Green arrows represent the putative 
positive CSRs encoding genes: SNA00088 (LysR-family); SNA00096 (Cyclic AMP (cAMP) receptor protein). 
White arrows represent other genes. 
Once formed, either by MVA or MEP pathways, IPP is rearranged by isopentenyl 
diphosphate:dimethylallyl diphosphate isomerase (IPP isomerase), to form dimethylallyl 
diphosphate (DMAPP) (Dairi, 2005).  
The condensation of DMAPP with one, two or three IPP units gives rise to geranyl 
diphosphate (GPP), farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP) that 
once cyclized by terpene synthases, constitute the parent skeletons of monoterpenes (C10), 
sesquiterpenes (C15) and diterpenes (C20). Two farnesyl units joined head-to-head by 
squalene synthase (SQS) lead to the formation of squalene, the precursor of triterpenes (C30). 
Tetraterpenes (C40) are formed from two geranylgeranyl units joined head-to-head by 
phytoene synthase (PSY), originating phytoene as an intermediate. Terpenes structural 
backbones can be further modified by hydroxylation, methylation and glycosylation, among 
others. It should be noted that terpene synthases are also referred as terpene cyclases 
(Greenhagen and Chappell, 2001). 
BLASTp and protein domain analysis of SNA00095 identified a terpene synthase metal-
binding domain-containing protein between amino acid 60 and 367 (PFAM03936) with 82% 
identity (306 aa/373 aa) with the one from Streptomyces violaceusniger Tu 4113 (Table A1) 
which corroborates the antiSMASH prediction. Furthermore, SNA00095 also shares 79% 
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identity (296 aa/374 aa) with a 2-methylisoborneol (MIB) synthase from Streptomyces sp. 
NRRL S-237. This enzyme is involved in the formation of the monoterpene MIB (Fig. 6A) – an 
organic chemical with a strong odour, which is one of the chemicals with major influence on 
the quality of drinking water (Newcombe and Cook, 2002). MIB biosynthesis is associated to 
clusters that include, besides the monoterpene cyclase, a cyclic nucleotide-binding protein and 
a methyltransferase, which are both also present in S1C1: SNA00096 [73% identity (52 aa/71 
aa) with Streptomyces sp. NRRL S-237] and SNA00094 [88% identity (261 aa/ 265 aa) with 
Streptomyces sp. NRRL S-237], respectively (Fig. 6B). The results suggested that S1C1 may be 
responsible for the production of a MIB analogue or structurally related compound. 
 
Figure 5 – Schematic representation of terpenes biosynthesis. Once formed either from MEP or MVA pathways, IPP 
is converted to its allylic isomer DMAPP, by IPPI. The condensation of one, two or three molecules of IPP 
to DMAPP, by GPPS, FPPS or GGPP, respectively, lead to the formation of GPP, FPP or GGPP. In turn, two 
molecules of FPP, by SQS, or GGPP, by PSY give rise up to squalene or phytoene respectively. The latter 
compounds, as well as GPP, FPP and GGPP, once cyclised by terpene synthases give rise to 
monoterpenes, sesquiterpenes or diterpenes, respectively. (G3P, glyceraldehyde-3-phosphate; MEP, 2-
C-methyl-D-erythritol 4-phosphate; MVA, mevalonate; IPP, isopentenyl diphosphate; IPPI, isopentenyl 
diphosphate isomerase; DMAPP, dimethylallyl diphosphate; GPPS, geranyl diphosphate synthase; GPP, 
geranyl diphosphate; FPPS, farnesyl diphosphate synthase; FPP, farnesyl diphosphate; GGPPS, 
geranylgeranyl diphosphate synthase; GGPP, geranylgeranyl diphosphate; SQS, squalene synthase; PSY, 
phytoene synthase) [Adapted from Schmidt et al., 2010]. 
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Flanking the core S1C1 region (SNA00094-SNA00096) it can be identified putative 
tailoring enzymes encoding genes, i.e., enzymes that further functionalize the terpene 
molecule, particularly SNA00100, SNA00101 and SNA00102. SNA00102 was identified as a 
putative decarboxylase. These enzymes, also known as carboxy-lyases, are able to 
decarbolxylate their substrates, releasing carbon dioxide (Ochoa, 1951). They have already 
been shown to be responsible for generating structural diversity in some cases during the 
maturation of secondary metabolites (Rachid et al., 2010).  
 
 
Figure 6 – 2-methylisoborneol (MIB). A). Chemical structure. B). Organization of the biosynthetic gene cluster, 
including the predicted monoterpene cyclase (black arrows) and flanking genes in different Streptomyces 
strains. Greyed and brown arrows represent cyclic nucleotide-binding protein and methyltransferase 
genes, respectively [Adapted from Komatsu et al., 2008]. 
Regarding CSR proteins, S1C1 presented two putative positive transcriptional regulators: 
SNA00088 from the LysR family and SNA00096, a cAMP receptor protein (CRP)/fumarate and 
nitrate reduction regulatory protein (FNR)-type transcription factor (Table A7). SNA0096 was 
not identified as a regulator by antiSMASH. However the in silico analysis performed has 
shown that it is part of the terpene biosynthetic cluster. 
3.1.1.2 Assessing the transcription of selected genes of S1C1 biosynthetic gene cluster 
Cluster S1C1 holds two putative positive transcription regulators: SNA00088, from the 
LysR-family, and SNA00096, from CRP/FNR-family. The transcription of both encoding genes 
was assessed together with SNA00095, a structural gene that encodes a putative terpene 
synthase (Fig. 7). RT-PCR results showed that the putative transcription regulator encoding 
gene SNA00096 is being transcribed in both strains, as well as the putative structural gene 
SNA00095. Conversely, SNA00088 is being poorly expressed in both wild-type and ΔpimM 
strains. Regarding the differences between strains, in spite of the variations observed in 
biological replicates, it seems that the transcript levels of SNA00095 and SNA00096 are higher 
in ΔpimM. 
These results pointed out S1C1 as a non-silenced gene cluster because the structural 
gene SNA00095 is being expressed. Nevertheless production of terpenes has not been 
described in S. natalensis. To overproduce this metabolite, overexpressing SNA00096 might be 
A B 
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strategy, since it was predicted by the in silico analysis as a putative positive regulator and its 
expression pattern is similar to the one presented by SNA00095. The low transcription levels of 
SNA00088, another predicted positive CSR, suggest that it is in a different regulatory lawyer. 
Therefore, its overexpression could also work as a viable approach for increasing the terpene 
production.  
 
Figure 7 – Transcription analysis of S1C1 selected genes by RT-PCR. Transcripts of SNA00095 (terpene synthase 
encoding gene), SNA00088 (LysR-family encoding gene) and SNA00096 (CRP/FNR-family encoding 
gene), 16S rRNA (positive control) and pimS1 (positive control for WT and negative control for ΔpimM) 
were analysed by RT-PCR with 30 cycles on cDNA generated from RNA isolated at early stationary 
phase. Two biological replicates are shown for each strain. 
3.1.2 S1C2 – a putative type II PK-terpene hybrid biosynthetic gene cluster 
3.1.2.1 In silico analysis 
Cluster S1C2 was identified by antiSMASH as a hybrid type II PKS-terpene (Fig. 9), 
meaning that the final compound may have mixed characteristics between a type II polyketide 
and a terpene. Polyketides are a large family of structurally diverse natural products that 
possess a wide range of pharmacological properties (e.g. antibacterial, antitumor, insecticide, 
among others) and display a vital role in human and veterinary medicine (Moore and 
Hertweck, 2002). The production of these compounds share common mechanisms with fatty 
acids biosynthesis. Indeed, each repetitive elongation step involves a Claisen condensation, 
where acyl extender units are incorporated into the growing chain. However, in fatty acids 
biosynthesis each elongation step is followed by a complete cycle of reductive reactions, such 
as ketoreduction, dehydration, and enoylreduction which may or not occur in polyketides 
synthesis, leading to the formation of far more chemically diverse products (Aparicio et al., 
2002). The backbone of polyketides is synthesised by polyketide synthases, which can be 
categorized into: type I (PKS-I), type II (PKS-II) – majorly found in microorganisms – and type III 
PKS (PKS-III) – more common in plants, even though some Streptomyces strains harbour genes 
encoding for this kind of enzymes (Yu et al., 2012). PKS-I, also known as modular PKSs, are 
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multifunctional and multimodular proteins that are mostly involved in the synthesis of 
macrolides. Each PKS-I is composed by at least one module with three core catalytic domains 
(minimal module): acyltransferase (AT), acyl carrier protein (ACP) and ketosynthase (KS). This 
minimal module is responsible for an elongation cycle, i.e. incorporation of an extender unit 
(e.g. malonyl-CoA). In addition to these catalytic domains, PKS-I modules may also contain 
domains that alter the reduction state of the growing chain in a NADPH-dependent manner, 
such as β-ketoreductase (KR), dehydratase (DH) and enoylreductase (ER). When the polyketide 
growing chain reaches the final module, elongation is terminated and the molecule is released 
by hydrolysis through the action of a thioesterase domain (TE). In contrast to the type I PKS, 
type II PKS, or iterative PKS, are multienzymatic complexes mainly involved in the production 
of aromatic polyketides (e.g. tetracyclines and actinorhodin). These enzymes elongate 
polyketides through repetitive condensation reactions catalysed by heterodimers composed 
by ketosynthase and ACP, in an iterative way. Furthermore, PKS-II presents a high degree of 
substrate specificity, mostly using acetyl-CoA and malonyl-CoA as starter and extender units, 
respectively. After the condensation procedure, the aromatic polyketides can be reduced by 
ketoreductase and modified by enzymes like aromatases, cyclases or glycosylases (Hwang et 
al., 2014). 
Regarding cluster synteny, S1C2 ClusterBlast analysis revealed two regions (SNA00394-
SNA00402 and SNA00409-SNA00435) that shared high similarity and synteny with homologous 
gene clusters from Streptomyces (Fig. 8), i.e. homologous genes have identical co-localization 
within the different genomes of the different species. Individual BLASTp analysis for each gene 
unveiled that the conserved regions hold core genes responsible for the production of a 
terpene (SNA00409-SNA00435) and for a type II PKS (SNA00394-SNA00402) (Fig. 9; Table A2). 
It should be noted that core genes are intended to be specifically related with the biosynthesis 
of the backbone of the corresponding metabolite. 
BLASTp analysis of each gene within the type II PKS conserved region (SNA00393-
SNA00905) revealed the presence of the three enzymes that constitute a PKS minimal module: 
SNA00397, a putative polyketide chain length factor, SNA00398, a putative polyketide beta-
ketoacyl synthase and SNA00396, a putative ACP (Table A2). Genes coding for these proteins 
and surrounding ones (SNA00393-SNA00401) showed high degree of identity with the whi 
locus of S. coelicolor (Fig. 10) involved in the production of the polyketide spore-associated 
grey pigment. Protein domain analysis identified a putative SchA/CurD domain (PFAM04486) 
in SNA00400, located between aa 137-251. These domain containing proteins function is 
unknown, but they have been identified as be part of gene clusters involved in the synthesis of 
polyketide-based spore pigments (Blanco et al., 1993). 
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Figure 8 – Schematic representation of cluster S1C2. Brown arrows represent putative structural genes. The upper ones (from SNA00393 to SNA00401) are likely to be involved in the 
biosynthesis of a polyketide, while the other lower ones are likely to be involved in the biosynthetic pathway of a terpene (from SNA00409 to SNA00432). Blue arrows represent 
putative transporters encoding genes: SNA00419, SNA00420 and SNA00431. The green arrow represents the putative positive CSR encoding genes: SNA00432 (AraC-family). The 
red arrow represents a putative negative transcription regulator encoding gene: SNA00404 (XRE-family). Yellow arrows represent genes that code for putative CSRs which may 
either act as activators or repressors: SNA00403 (AbaA-like protein); and SNA00428 (putative regulatory protein). White arrows represent other genes. 
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Figure 9 – Top five S1C2 homologous gene clusters regarding synteny. Homologous genes are shown in identical 
colours, whereas white-coloured genes have no Blast hits between the gene clusters. Putative PKS-II 
biosynthetic core genes are marked within blue boxes (A), while putative terpene biosynthetic genes are 
marked within orange boxes (B). In S. natalensis ATCC 27448 the dashed box is localized between 
SNA00392 and SNA00401, while the non-dashed is localized between SNA00409 and SNA00435. 
Accession numbers: S. griseoflavus Tu4000 – NZ_GG657758.1_c4; S. viridochromogenes DSM 40736; S. 
hygroscopicus ATCC 53653 – NZ_GG657757.1_c24; S. albus J1074 – NZ_GG657754.1_c12; S. 
hygroscopicus subsp. Jingangensis 5008 – NZ_DS999645.1_c18. 
 
Figure 10 – Organization of the S1C2 putative polyketide subcluster in S. natalensis ATTC 27448, together with 
the whiE cluster in S. coelicor A3(2). (O-MTR, O-methyltransferase; CYC, cyclase; ARO, aromatase; ACP, 
acyl carrier protein; CLF, chain length factor; KS, ketosynthase; SchA/SurD, SchA/SurD domain 
containing protein; MO, monooxygenase; HYDR, hydroxylase) [Adapted from Kelemen et al., 1998]. 
Assuming that the type II-PKS its responsible for the biosynthesis of the spore-associated 
pigment and that in other Streptomyces strains this cluster do not have an associated terpene 
sub-cluster (Bentley et al., 2002), we can hypothesise that S1C2 is not a hybrid cluster. 
Moreover, to the best of our knowledge, a hybrid PKS-II-terpene cluster has not been 
described in the literature.  
Regarding post-PKS encoding genes, SNA00393 codes for a putative O-
methyltransferase, and SNA00401 codes for a putative monooxygenase, suggesting the 
introduction of a methyl group or/and a hydroxyl group in the final polyketide molecule. 
Regarding the terpene core genes, BLASTp analysis revealed the presence of a 1-deoxy-
D-xylulose-5-phosphate synthase (DSX) encoding gene (SNA00410). This enzyme is responsible 
for the first committed step of the MEP pathway, suggesting that this terpene is produced 
through this pathway (Fig. 11). Moreover, an IPP delta-isomerase (SNA00427), a 
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dimethylallyltranstransferase (SNA00414), a phytoene synthase (PSY) (SNA00416), a squalene 
synthase (SQS) (SNA00417), and a squalene/phytoene dehydrogenase – SNA00415 (identity of 
85% (379/445)) – were also identified (Table A2; Fig. 11). The presence of these proteins 
suggest that the end terpene should have a similar structure as squalene or/and phytoene. 
 
Figure 11 – Schematic representation of the proposed possible biosynthetic pathways for the S1C2 terpene 
biosynthesis. Once formed by from MEP pathway, IPP is isomerized into DMAPP by an IPP delta-
isomerase, coded by SNA00427. Next, dimethylallyltranstransferase, coded by SNA00414, converts 
DMAPP and IPP into FPP (GPP is created in an intermediate step). Then, either (1) FPP can be 
condensed with another FPP molecule to form SQ or (2) it undergoes the addition of another 
molecule of IPP to form GPP. If (1), SQS, coded by SNA00417, is the enzyme that catalyses the 
mentioned reaction. Once generated, the SQ is converted into 2,3-oxidosqualene. The latter can then 
be converted into lanosterol by the lanosterol synthase (an enzyme not identified within S1C2 gene 
cluster). If (2), the dimethylallyltranstransferase also acts as GGPPS, leading to the formation of GGPP. 
Two molecules of GGPP can be then condensed by PSY, coded by SNA00416, to originate PE. Next, PD 
converts PE into β-carotene. It may also be possible that the end product results for a combination of 
both of the later biosynthetic pathways. (G3P, glyceraldehyde-3-phosphate; DXS, 1-deoxy-D-xylulose 
5-phosphate synthase; DOXP, 1-deoxy-D-xylulose 5-phosphate; MEP, 2-C-methyl-D-erythritol 4-
phosphate; IPP, isopentenyl diphosphate; IPPI, isopentenyl diphosphate isomerase; DMAPP, 
dimethylallyl diphosphate; FPPS, GGPPS, dimethylallyltranstransferase; FPP, farnesyl diphosphate; 
SQS, squalene synthase; SQ, squalene; SM, squalene dehydrogenase; GGPP, geranylgeranyl 
diphosphate; PSY, phytoene synthase; PE, phytoene; PD, phytoene dehydrogenase). 
Furthermore, the identification of 11 putative tailoring genes suggests a highly modified 
end product. A glycosyl transferase (SNA00421), a mannose-1-phosphate guanylyltransferase 1 
(SNA00424), a putative dehydrogenase (SNA00423), two aminotransferases (SNA00409 and 
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SNA00419), a glutamine amidotransferase (SNA00432) and two transferases (SNA00422 and 
SNA00425) – have been identified as tailoring genes. 
Regarding CSR, the antiSMASH analysis retrieved two regulators: an AraC-family 
member (SNA00399) and a protein assigned as regulatory protein (SNA00428). Manual 
curation unveiled the presence of three additional putative CSR: an AbaA-like protein 
(SNA00403), a XRE-like protein (SNA00404) and an AraC-family member (SNA00433) (Table 
A2). Moreover, SNA00399 should not encode for a regulator. Instead, as previously 
mentioned, it should encode for a polyketide cyclase that holds a cupin domain between aa 
41-111 (PFAM07883). From the remaining four proteins, one is likely to act positively: 
SNA00433 (AraC-family member). SNA00404 (coding for a XRE-like protein) is likely to be a 
negative regulator. Based on protein prediction we were not able to assign a regulatory 
function to SNA00403 (an AbaA-like protein) and SNA00428. In an attempt to identify the 
subcluster regulators just by the distance to the core biosynthetic genes, it can be said that 
SNA00428 and SNA00433 belong to the terpene subcluster. Since SNA00403 and SNA00404 
are equally close to both subclusters core genes (approximately 3 and 5 kb to the PKS-II and 
terpene subclusters, respectively) they can regulate either or even both. 
As a final remark of S1C2 biosynthetic gene cluster it should be mentioned that it is 
possible that both PKS-II and terpene sub-clusters may be involved in the production of the 
same metabolite. However, due to (1) the cluster and subcluster analysis, (2) the distance 
between them (approximately 8 kb) and (3) the chemical families of the predicted compounds, 
it is likely that they do not form a hybrid cluster, but are two clusters coding for a type II PKS 
(SNA00394-SNA00402), hereafter named S1C2.1, and a terpene (SNA00409-SNA00435) 
hereafter named S1C2.2. In that case, S1C2 may stand as an example of what could be a 
weakness of antiSMASH, emphasizing the importance of manual curation of the results 
presented by the software. Nevertheless, the confirmation of the hybrid nature of the cluster 
can only be achieved through a functional characterization of the clusters and, more 
importantly, through the isolation and structure characterization of the final compound. 
3.1.2.2 Assessing the transcription of selected genes of S1C2 biosynthetic gene cluster 
Cluster S1C2 was assigned by antiSMASH as a hybrid PKS-terpene cluster. For 
transcription studies, three structural genes, two of S1C2.1 sub-cluster and one of S1C2.2 sub-
cluster, have been selected: SNA00397, a polyketide chain elongation factor (also referred as a 
ketosynthase) encoding gene, SNA00399, a gene coding for a polyketide cyclase and SNA00414 
that codifies for a putative dimethylallyltranstransferase. Furthermore, the putative regulators 
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encoding genes, SNA00403 (AbaA-like protein), SNA00404 (XRE-family), SNA00428 and 
SNA00433 (AraC-family) have also been selected (Fig. 12). 
 
Figure 12 – Transcription analysis of S1C2 selected genes by RT-PCR. Transcripts of SNA00397 (polyketide chain 
elongation factor encoding gene), SNA00399 (AraC-family encoding gene), SNA00414 
(dimethylallyltransferase encoding gene), SNA00403 (AbaA-like encoding gene), SNA00404 (XRE-family 
encoding gene), SNA00428 (regulatory protein encoding gene), SNA00433 (AraC-family encoding 
gene), 16S rRNA (positive control) and pimS1 (positive control for WT and negative control for ΔpimM) 
were analysed by RT-PCR with 30 cycles on cDNA generated from RNA isolated at early stationary 
phase. Two biological replicates are shown for each strain.  
Overall, no differences between the two strains were observed. Regarding the 
polyketide structural genes SNA00397 and SNA00399 no transcripts were detected in both 
strains (Fig. 12). This fact is consistent with the in silico prediction that this polyketide sub-
cluster could be responsible for the production of the grey spore pigment. In fact, it was 
observed, during the present project, that S. natalensis does not sporulate in liquid medium, as 
it happens for some Streptomyces (Yague et al., 2012). Therefore, these transcription results 
further comprove the mentioned observation. 
The terpene structural gene SNA00414 was expressed in both the wild-type and ΔpimM 
strains. This suggests that the terpene sub-cluster is not silent and, additionally, strengthens 
the hypothesis that S1C2 is indeed two independent sub-clusters rather than of a hybrid one 
as predicted by antiSMASH. 
Regarding the terpene cluster associated transcription regulator genes, SNA00428 was 
transcribed in both strains, while SNA00433 presented low transcript levels. As a regulator 
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with no assigned category by in silico prediction, the results suggest SNA00428 as a positive 
CSR that might be directly or indirectly regulating SNA00414. In turn, SNA00403 as a predicted 
positive transcription regulator seems not to be directly involved in the transcription of the 
studied structural gene. Nevertheless, it may still work as a positive CSR, regulating indirectly 
the expression of the studied gene or acting on only part of the cluster structural genes. 
Lastly, both SNA00403 and SNA00404 presented high transcription levels. Since 
SNA00404 was identified by in silico analysis as a negative regulator, and since only the 
terpene structural gene is being expressed, it is likely that this putative regulator is part of the 
polyketide sub-cluster. In turn, SNA00403, since its role as a regulator was not foreseen, may 
either act as a positive regulator in the terpene sub-cluster or as a negative regulator in the 
polyketide sub-cluster. 
3.1.3 S1C3 – a putative type III PK biosynthetic gene cluster 
3.1.3.1 In silico analysis 
As above mentioned, PKS-III are mostly found in plants. In fact, it was proposed that 
type III PKS were plant specific. However, several studies have shown that they are widely 
present in bacteria and in fungi (Yu et al., 2012). These PKSs are simple homodimers of 
ketosynthases that do not use ACP for the carbon chain elongation and act directly on the 
extender units (acyl-CoAs) to catalyse iterative condensations (Fujii, 2008, Song et al., 2006, Yu 
et al., 2012).  
S1C3 (Fig. 13), was identified by antiSMASH as encoding a type III PKS that presented 
low synteny with other Streptomyces.  
BLASTp analysis of the proteins coded by S1C3 cluster (Table A3) retrieved a type III PKS, 
SNA00841 (89% identity with RppA from Streptomyces albulus), and a cytochrome P450, 
SNA00843 (84% identity with a cytochrome P450 from Streptomyces albulus). The co-existence 
of a PKS-III and a cytochrome P450 encoding genes in the same cluster is a feature observed in 
other streptomycetes type III PKS biosynthetic gene clusters (Fig. 14) (Funa et al., 2005). The 
RppA of Streptomyces griseus, homologous to SNA00841, was the first bacterial PKS identified 
as a member of the chalcone synthase (CHS) superfamily and categorized as a PKS-III (Funa et 
al., 1999). Furthermore, the association of RppA with the production of melanin in S. griseus 
(Funa et al., 2002) together with the similarity between the RppA encoding gene from S. 
griseus with other cluster situated RppA-like enzymes suggested the involvement of these 
enzymes in the biosynthesis of a wider range of secondary metabolites (Bangera and 
Thomashow, 1999, Pfeifer et al., 2001, Funa et al., 2002). 
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Figure 13 – Schematic representation of cluster S1C3. Brown arrows represent putative structural genes. Blue arrows represent putative transporters encoding genes (SNA00839 and 
SNA00859). The red arrows represent putative negative CSR encoding genes: SNA00835 (XRE-family); and SNA00851 (TetR-family). The yellow arrow (SNA00830) represents a 
putative CSR encoding gene which may either act as activators or repressors: SNA00830. White arrows represent other gene.  
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Figure 14 – Schematic representation of some type III PKS gene clusters from streptomycetes. Each arrow 
represents a different ORF. Grey arrows represent different rppA genes coding for type III PKS, while 
black arrows represent different P-450 encoding genes. The white arrow represents a hypothetical 
protein [Adapted from Zeng et al., 2012]. 
 BLASTp analysis also allowed to identify the putative tailoring genes, which may be 
responsible for the modification of the compound post-PKS. Two of these genes encode for 
putative methyltransferases (SNA00831 and SNA00845) which suggests that the polyketide 
may suffer the addition of two (or more) methyl groups. Moreover, it was found the presence 
of a gene coding for a putative alcohol dehydrogenase (SNA00847) and for a putative 
acetyltransferase (SNA00849). These enzymes catalyse the interconversion between alcohols 
and aldehydes or ketones and the transference of an acetyl group, respectively. Thus, the end 
polyketide molecule may contain an extra acetyl group and one of its acyl groups may be 
converted into a hydroxyl group (OH). Additionally two genes coding for putative transporters 
have been identified (SNA00839 and SNA00859). 
It is also interesting to note that SNA00841 and SNA00843 seem to be surrounded by 
genes somehow involved in the modification or transport of proteins (from SNA00840 to 
SNA00859), namely SNA00840 that encodes for a putative aminopeptidase and SNA00855 that 
encodes for a putative S15 family peptidase, among others. Thus, it is likely that those genes 
that appear to be involved in the peptide metabolism will further functionalize the type III 
polyketide. 
Only two putative regulators were identified, notably SNA00835 (XRE-family) and 
SNA00851 (TetR-family). SNA00830 was also identified as encoding a putative regulator 
although no domains were detected in the amino acid sequence that could unveil its role. 
3.1.3.2 Assessing the transcription of selected genes of S1C3 biosynthetic gene cluster 
S1C3 was identified as a type III PKS encoding cluster. The PKS-III encoding gene 
SNA00841 was chosen for transcription analysis together with the putative transcription 
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regulators encoding genes: SNA00830, SNA00835 and SNA00851. Results are displayed in 
Figure 15. 
 
Figure 15 – Transcription analysis of S1C3 selected genes by RT-PCR. Transcripts of SNA00841 (PKS-III encoding 
gene), SNA00830 (regulator encoding gene), SNA00835 (XRE-family encoding gene), SNA00851 (TetR-
family encoding gene), 16S rRNA (positive control) and pimS1 (positive control for WT strains and 
negative control for ΔpimM strains) were analysed by RT-PCR with 30 cycles on cDNA generated from 
RNA isolated at early stationary phase. Two biological replicates are shown for each strain. 
Altogether, results showed no major differences between strains regarding the 
expression of S1C3 genes. The structural gene SNA00841 exhibited low transcription levels in 
the wild-type and in ΔpimM. This way, it was outstood the silent state of the cluster.  
SNA00851, encoding a putative TetR-family regulator, presented low transcription 
levels, similarly to the structural gene. This fact, together with its location and predicted 
regulatory activity suggests SNA00851 as a positive CSR involved in the control of the PKS-III 
encoding gene transcription. Although TetR family is mostly composed by transcription 
repressors (Ramos et al., 2005), there are some documented examples of transcription 
activators on this family. One of such cases is the Clostridium tetani CN655 TetR that was 
shown to be a positive regulator of the tetanus toxin gene (tetX) (Marvaud et al., 1998). The 
XRE-family member SNA00835 was transcribed in both strains, which suggests that it acts as a 
repressor of this gene cluster. Interestingly, this fact is consistent with the prediction of the 
present gene be coding for a negative regulator. Lastly, the inconsistent expression pattern of 
SNA0830 in biological replicates does not allow any prediction regarding its function. 
3.1.4 S1C4 – a putative bacteriocin biosynthetic gene cluster 
3.1.4.1 In silico analysis 
Bacteriocins are peptides produced by many bacteria with the purpose of inhibiting the 
growth of similar or closely related bacterial strains, which may exercise competition in milieu 
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(Karpiński and Szkaradkiewicz, 2013, Nigam et al., 2014). These compounds are widely used as 
food preservative (Cleveland et al., 2001) and in the clinical practice against bacterial 
pathogens, cancer, and anti-inflammatory diseases (Karpiński and Szkaradkiewicz, 2013). 
A relatively short precursor peptide is first translated and then modified. This 
modification includes at least one proteolytic step that cleaves the precursor peptide on its N-
terminal extension, at specific processing sites, giving rise to a smaller and active fragment 
(Fig. 16). The N-terminal leader sequence presumably facilitates interaction with the 
transporter and/or keeps the peptide inactive until it has been secreted from the cell. Further 
post-translational modifications, such as macrocyclization or formylation, among others, may 
also take place. The end bacteriocin must be then secreted, by the action of transporters. In 
some cases, as it happens in nisin biosynthesis, the export is tightly coupled to proteolysis 
(McIntosh et al., 2009). As a final note regarding bacteriocin biosynthesis, the genes encoding 
precursor peptides often cluster with genes encoding modifying enzymes, secretion, and also 
immunity/resistance genes. 
  
Figure 16 – Bacteriocins biosynthesis. The gene encoding for the precursor peptide, usually clustered with genes 
encoding modifying enzymes, secretion, and also immunity genes, is initially transcribed and then 
translated. Then, posttranslational modifications take place, including a proteolytic cleavage allows the 
separation of the leader peptide from the active peptide [Adapted from McIntosh et al., 2009]. 
 
S1C4 (Fig. 17), a cluster predicted to be responsible for the biosynthesis of a bacteriocin, 
displayed low synteny with homologous gene clusters presented by antiSMASH. Analysis of the 
25 genes that are part of S1C4 (Table A4) showed that two may encode the bacteriocin 
Page 40 
precursor peptide: SNA01164 and SNA01165. Despite the fact that BLASTp retrieved 
homologies with hypothetical proteins (Table A4) protein domain analysis showed that both 
proteins have a TIGR04222 domain (from aa 1 to aa 241 and from aa 7 to aa 254, respectively). 
The majority of the proteins with a TIGR04222 domain as described by this model have a C-
terminal sequence that consists of extremely low-complexity sequence, rich in Ser or in Gly 
interspersed with Cys that is present in SNA01164. That C-terminal region resembles ribosomal 
natural product precursors, although there is no evidence that C-terminal regions of these 
proteins undergo any modification or have any such function (Marchler-Bauer et al., 2013). 
Furthermore, SNA01166 encodes a putative tripeptidyl aminopeptidase (TAP) (71% identity). 
TAP is a member of the S33 peptidase family, a subgroup of serine proteases with amino 
proline peptidase activity (Rawlings and Barrett, 1994). Thus, it can be hypothesized that 
SNA01166 encodes the proteolytic enzyme responsible for the cleavage of the peptide 
precursor. 
 
Figure 17 – Schematic representation of cluster S1C4. The brown arrow represents SNA01166 that encodes a 
putative tripeptidyl aminopeptidase that might work as the proteolytic enzyme responsible for the 
cleavage of the peptide precursor. The orange arrows represent SNA01164 and SNA01165, two genes 
encoding for putative hypothetical proteins that hold a TIGR04222 domain. These domains are typical 
in proteins with a C-terminal region that resembles ribosomal natural product precursors. Purple 
arrows represent genes encoding for enzymes related with fatty acids metabolism. Blue arrows 
represent putative transporters encoding genes. The green arrow represents SNA01173 that encodes 
a putative positive CSR (LuxR-family). White arrows represent other genes. 
Three genes appear to be involved in degradative pathways of fatty acids: SNA01169, 
that codes for a putative beta-ketoadipyl CoA thiolase, SNA01177, which encodes a putative 
acetyl-CoA acetyltransferase and SNA01178, which encodes a putative 3-hydroxyacyl-CoA 
dehydrogenase. It is currently known that the addition of isoprene-derived subunits to a core 
molecule (prenylation) is a post translational reaction extremely common in the natural 
products world. Since the final products of fatty acids degradation are precursors for the 
biosynthesis of terpenes the presence of the mentioned three genes suggests that isoprene 
precursors may further be added to the bacteriocin. 
Two genes coding for ABC transporters (SNA01158 and SNA01159) were also identified. 
These proteins could be involved in the secretion of the bacteriocin synthesized by S1C4. 
Lastly, it has been determined that S1C4 contains a putative positive regulator: 
SNA01173. This gene has been identified as coding for a LuxR-family member. Moreover, the 
protein domain analysis revealed the presence of a signal receiver domain, that receives the 
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signal from the sensor partner in a two-component systems (aa 1-112) and a C-terminal DNA-
binding domain of LuxR-like proteins (aa 138-194). 
3.1.4.2 Assessing the transcription of selected genes of S1C4 biosynthetic gene cluster 
S1C4 was identified by antiSMASH as a bacteriocin biosynthetic gene cluster. From all its 
twenty five genes, as none clearly identified as a prepeptide encoding gene, SNA01166, that 
encodes a putative TAP, was believed to be the most likely to be related with bacteriocins 
biosynthesis, which justified its selection for RT-PCR experiments. Concerning to transcription 
regulators, only SNA01173 (LuxR-family) was identified and hence subjected to the 
transcription analysis.  
The transcription of both genes was residual in both strains (Fig. 18), suggesting that this 
cluster was silent in the wild-type and in ΔpimM strains. This result is coherent with the 
bioinformatics prediction of S1C4 being a bacteriocin type gene cluster, since these 
metabolites are produced during the primary phase of growth and mycelium samples were 
harvested at the beginning of the stationary phase (Beasley and Saris, 2004). In addition, it can 
be rightly argued that the repressed state of SNA01173, together with its genomic location and 
predicted in silico characterization, indicates that it acts as the positive regulator of this cluster. 
Therefore, SNA01173 was selected for overexpression towards S1C4 activation. 
 
Figure 18 – Transcription analysis of S1C4 selected genes by RT-PCR. Transcripts of SNA01166 (TAP encoding gene), 
SNA01173 (LuxR-family encoding gene), 16S rRNA (positive control) and pimS1 (positive control for WT 
strains and negative control for ΔpimM strains) were analysed by RT-PCR with 30 cycles on cDNA 
generated from RNA isolated at early stationary phase. Two biological replicates are shown for each 
strain. 
3.1.5 S1C5 – a putative NRP biosynthetic gene cluster 
3.1.5.1 In silico analysis 
Nonribosomal peptide synthetases (NRPS), are multimodular and multifunctional 
enzymes, known for their ability to produce bioactive compounds using amino acids in both 
the L- and D- forms as precursors (Hwang et al., 2014). NRPS are composed of distinct 
modules, each one responsible for the incorporation of one specific amino acid into the final 
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product. By their turn, modules are subdivided into catalytically independent domains, namely 
adenylation (A), peptidyl carrier protein (PCP or thiolation) and condensation (C). The A 
domain is responsible for the recognition and consequent activation of the amino acid building 
block by the formation of an amino acyl adenylate intermediate. Then, the activated substrate 
is transferred to the PCP where it is covalently bound through a thioester linkage, leading to 
the activation of this domain. Finally, C domain is responsible for the peptide bond formation 
with the downstream amino acyl unit that is tethered to the PCP of the adjacent module 
(Sieber and Marahiel, 2005). The last module presents a thioesterase (TE) domain that 
terminates the elongation process, releasing the molecule. In some cases it can also be found 
epimerization domains (E), which are responsible for the conversion of the PCP tethered 
aminoacyl substrate from the L to the D form (Fischbach and Walsh, 2006, Rix et al., 2002, 
Walsh and Fischbach, 2010). 
S1C5 (Fig. 19) was retrieved by antiSMASH as a putative nonribosomal peptide encoding 
biosynthetic gene cluster. Two large NRPS encoding genes were identified: SNA01225 (8148 
bp) and SNA01226 (18966 bp) (Table A5). 
The first, SNA01225 displayed two modules, predicted to incorporate two amino acids. 
In turn, SNA01226 has five modules. Therefore it is predicted to incorporate five amino acids. 
AntiSMASH amino acid prediction based on the A domains retrieved that the module 3 
and 4 from SNA01226 should introduce an alanine into the end product, while SNA01225 first 
module should incorporate a valine (Fig. 20). SNA01225 sequence displayed a TE domain at the 
end which may indicate the end of the compound biosynthesis. However three additional 
NRPS domain encoding genes were also identified from the protein domain analysis: 
SNA01211 (PCP); SNA01212 (A domain); SNA01213 (TE domain). These three domains may 
function as an additional NRPS module predicted to introduce a threonine residue. 
Worth to note that if the TE domain present in SNA01213 is actually part of the module 
constituted by SNA01211 (PCP) and SNA01212 (A domain) there will be two TE domains in the 
NRPS. To the best of our knowledge, until this date no NRPS system has been described as 
holding two TE domains. Alternatively, SNA01211 and SNA01212 could constitute a loading 
module responsible for feeding SNA01226 with a shorter unit which could be a threonine. 
The S1C5 ClusterBlast analysis showed a high level of synteny with the biosynthetic gene 
cluster of himastatin from Streptomyces himastatinicus ATCC 53653 (Fig. 21). Particularly the 
genomic region that includes genes SNA01215 to SNA01224. 
Himastatin is synthethized by a 7-module NRPS and its structure harbours an unusual 
symmetric cyclohexadepsipeptide dimer and a peptidyl backbone (Fig. 22). 
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Figure 19 – Schematic representation of cluster S1C5. The brown arrows represent the structural genes, including the core NRPS synthases encoding genes SNA01211, SNA01212, SNA01213, 
SNA01225 and SNA01226. Pink arrows represent peptide modifying enzymes encoding genes that may or may not be involved in the NRP tailoring. Blue arrows represent putative 
transporters encoding genes: SNA01218 and SNA01219. Green arrows represent SNA01193 (RNA polymerase sigma factor) and SNA01239 (MerR-family) that encode for putative 
positive CSRs, while red arrows represent putative negative CSRs: SNA01232, SNA01256 and SNA01258 (TetR-family); SNA01250 (DeoR-family); and SNA01254 (PaaX-family). 
White arrows represent other genes. 
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Figure 20 – AntiSMASH prediction for protein domain specificities and chemical structure of the S1C5 NRP. 
SNA01226 A domain specificities suggest the incorporation of two alanines by the 3rd and 4th modules. 
In turn, SNA01225 A domain specificities suggest the incorporation of a valine by the 1st module. The 
module putatively formed by SNA01211 (PCP); SNA01212 (A domain); SNA01213 (TE domain) was 
predicted to incorporate a threonine. Modules with no assigned specific aminoacid hold isotope as 
residue. (A, adenylation domain; C, condensation domain; E, epimerization domain; nMT, N-
methyltransferase domain; TE, thiosterase domain; the PCP domains are represented by light blue 
balls). 
 
Figure 21 – Top S1C5 homologous gene cluster: himastatin biosynthetic gene cluster from Streptomyces 
himastatinicus ATCC 53653 (accession number FR823394.1_c1). Homologous genes are shown in 
identical colours, whereas white-coloured genes have no Blast hits between the gene clusters. The 
most conserved region between the two clusters is marked within a dashed box and includes three 
P450-like enzymes, one peptide monooxygenase and one methyltransferase encoding genes (green, 
red and light blue arrows, respectively). Other identical genes are represented by black arrows. 
It is a fact there are similarities between both himastatin biosynthetic gene cluster from 
Streptomyces himastatinicus ATCC 53653 and S1C5. Nevertheless, despite the fact that the end 
NRP produced from S1C5 could share resemblances with himastatin, it is clear that they will be 
to different compounds. Moreover, the differences between the two NRP molecules may then 
be translated in interesting alterations regarding their bioactivity. 
 
Figure 22 – Himastatin chemical structure [Adapted from Zhang et al., 2013]. 
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Regarding putative tailoring enzymes, SNA01226 owns itself one methyltransferase 
domain (from aa 941 to aa 1159). Additionally, two other putative methyltransferases 
encoding genes were also detected (SNA01243 and SNA01247). Thus, it is likely that the NRP 
undergoes three methylations, of which one should take place at the valine that is predicted to 
incorporate the growing chain (module 1 of SNA01225). Moreover, three P450-like enzymes 
(SNA01215, SNA01216 and SNA01231), two acetyltransferases (SNA01197 and SNA01222), 
two hydroxylases (SNA01251 and SNA01255), one alpha/beta hydrolase fold protein 
(SNA01209), one peptide monooxygenase (SNA01224), one aminotransferase (SNA01230) and 
one dehydrogenase (SNA01257) were identified. 
Worth to note that several putative peptide modifying enzymes related have been 
detected: SNA01202 (amidinotransferase); SNA01210 (chlorinating dioxygenases); SNA01214 
(peptidase); SNA01244 (biopterin-dependent aromatic amino acid hydroxylase family protein); 
and SNA01245 (pyridoxal-dependent amino acid decarboxylase). Thus, the NRP may further 
undergo through a functionalization performed by those enzymes typically involved in the 
peptide metabolism. 
Two ABC transporters (SNA01218 and SNA01219) were also detected. Therefore, it is 
possible that both SNA01218 and SNA01219 are part of the S1C5 NRP biosynthetic pathway as 
encoding proteins responsible for excretion of the end peptide. 
Regarding the CSRs present in this cluster, two putative transcription activators were 
identified: SNA01193 (an RNA polymerase sigma factor) and SNA01239 (a MerR-like protein). 
In addition, five genes encoding for putative negative regulators, three from TetR-like 
(SNA01232, SNA01256 and SNA01258), one belonging to the DeoR-family (SNA01250) and one 
of the PaaX-family (SNA01254) were also detected. It should be noted that SNA01193 is 
located approximately 20 kb from the biosynthetic core genes and most likely is not part of 
this cluster.  
3.1.5.2 Assessing the transcription of selected genes of S1C5 biosynthetic gene cluster 
For S1C5 transcription analysis, seven genes were selected: the putative transcription 
regulators SNA01239, SNA01239, SNA01250, SNA01254, SNA01256 and SNA01258 and a 
structural gene putatively encoding for a NRPS: SNA01225. 
As shown in Figure 23, the structural gene SNA01225 is poorly transcribed in both the 
wild-type and ΔpimM, suggesting that the transcription of S1C10 biosynthetic gene cluster is 
silenced in both strains. 
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Figure 23 – Transcription analysis of S1C5 selected genes by RT-PCR. Transcripts of SNA01225 (NRPS encoding 
gene), SNA01232 (TetR-family encoding gene), SNA01239 (MerR-family encoding gene), SNA01250 
(DeoR-family encoding gene), SNA01254 (PaaX-family encoding gene), SNA01256 (TetR-family 
encoding gene), SNA01258 (TetR-family encoding gene), 16S rRNA (positive control) and pimS1 
(positive control for WT and negative control for ΔpimM) were analysed by RT-PCR with 30 cycles on 
cDNA generated from RNA isolated at early stationary phase. Two biological replicates are shown for 
each strain. 
Regarding the results for the CSRs present in this cluster, SNA01239, similarly to the 
structural gene, also presented low transcript levels. This result, together with its in silico 
caractherization and genomic location, suggests that it may act as positive regulator. This way, 
SNA01239 overexpression stands as a promising strategy to awake this cluster and identify the 
final compound. 
With the exception of SNA01250, all the remaining genes encoding putative CSRs seem 
to have a high level of transcripts. Consequently, owing to their genomic location within S1C5 
and its in silico prediction, this protein might be involved in the repression of the gene cluster. 
Regarding the DeoR-family regulator encoding gene SNA01250, its repressed expression state 
may indicate that it acts as positive regulator. Such activity would not be expectable since 
DeoR-like regulators are usually repressors (Skerlová et al., 2014). However there are reported 
DeoR-family members that own a transcription activator role. The fruR gene from Spiroplasma 
citri that codes for a DeoR-family regulator activates the transcription of the fructose operon 
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(Gaurivaud et al., 2000, Gaurivaud et al., 2001) and stands as an example of the previously 
mentioned. 
It should also be mentioned that SNA01232 appears to have higher transcription levels 
in the ΔpimM strain rather than in the wild-type. This result, together with the fact that 
SNA01232 was predicted as a putative negative CSR according to bioinformatics analysis, may 
indicate that this protein is indeed repressing the activation of the structural gene.  
3.1.6 S5C20 – a putative type I PK-NRP biosynthetic gene cluster 
3.1.6.1 In silico analysis 
Polyketides and nonribosomal peptides, although different in overall structure and 
fundamental chemical building blocks, exhibit striking similarities in their biosynthetic 
assembly mechanisms. These similarities allow the formation of hybrid clusters that contain 
elements of each class (Du et al., 2001, Fisch, 2013). 
The combination of PKS and NRPS has already been described. In these systems, PKS and 
NRPS modules are combined in a hybrid modular system (Fisch, 2013). For example, in the 
antibiotic bacillaene biosynthesis, BaeJ protein combines three PKS with a NRPS module which 
incorporates glycine (Chen et al., 2006).  
S5C20 (Fig. 24) was identified as a hybrid PKS-NRPS biosynthetic gene cluster that 
presented low synteny with PKS-NRPS hybrid clusters. According to the presented functional 
annotation of its different domains, SNA06257 holds one A and one PCP domains, typical of 
NRPS system, and one PKS module comprising a KS-AT-DH-KR-ACP architecture (Fig. 25). 
Moreover, SNA06258 was identified as a TE encoding gene that could be responsible for the 
end of the elongation process. 
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Figure 24 – Schematic representation of cluster S5C20. The brown arrows represent the structural genes, such us the putative mixed PKS-NRPS encoding gene. Pink arrows represent peptide 
modifying enzymes encoding genes that may or may not be involved in the hybrid PK-NRP tailoring. Blue arrows represent putative transporter genes: SNA06273 and SNA06279 
(both putative DHA2-family drug resistance MFS transporters). Green arrows represent all the three putative positive CSR encoding genes: SNA06240 (LysR-family); SNA06245 
(AfsR-family); SNA06246 (LuxR-family). Red arrows represent putative negative CSRs encoding genes: SNA06231 (PadR-family); SNA06239 (GntR-family); SNA06243 (AsnC-family); 
and SNA06275 (TetR-family). Yellow arrow represent a gene encoding for a transcription regulator that might act as repressor or activator: SNA06261 (serine/threonine protein 
kinase). White arrows represent other genes. 
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Figure 25 – AntiSMASH prediction for protein domain specificities and chemical structure of the S5C20 hybrid PK-
NRP. AntiSMASH substrate specificities predictions of PKS and NRPS modules are based on the active 
sites of their corresponding AT and A domains. Thus, each AT and the A domain have an acyl-derivate 
or amino acid associated, respectively, even if they do not have the remaining domains required for a 
minimal PKS or NRPS. In the particular case of the NRPS, it is likely that the module may work as a 
loading one. Therefore, it does not require the lacking C domain at fault (AT, acyl transferase; A, 
adenylation domain; PCP, peptide carrier protein; KS, ketosynthase; DH, dehydrogenase; KR, 
ketoreductase; ACP, acyl carrier protein). antiSMASH prediction for protein domain specificities of 
S5C20. antiSMASH prediction for the core chemical structure of the final compound produced by 
S5C20. 
AntiSMASH amino acid and acyl units prediction based on the A and AT domains (for 
NRPS and PKS, respectively) retrieved that SNA06257 NRPS module introduces an unspecific 
amino acid, while the PKS module introduces a malonyl unit. Since the protein domain analysis 
showed that the NRPS module lacks a C domain required for a minimal NRPS, the NRPS 
domains should act as a loading module 
In addition to the molecular entities introduced by SNA06257, antiSMASH retrieved that 
two more acyl derivative units should also be incorporated into the hybrid PK-NRP molecule by 
two putative independent PKS modules. These modules include an AT domain suggested to be 
present in SNA06254 and in SNA06255. However, a minimal PKS requires, besides the AT 
domain, one ACP and one KS domains. Since it was not detected any KS and only one putative 
ACP (SNA06250) was identified in the putative mixed PKS-NRPS surrounding genes, it cannot 
be ascertain that the end compound will undergo through the addition of these two acyl 
derivative units. 
Concerning tailoring genes, one putative acetyltransferase has been detected 
(SNA06278) which indicates that the end product might have an extra acetyl group, and also 
several encoding proteins that catalyse typical reactions involving amino acids, namely a 
putative aminotransferase (SNA06241), a lysine 2,3-aminomutase (SNA06242) and a glycine 
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amidinotransferase (SNA06256). Thus, these enzymes involved in the peptide metabolism may 
further functionalize the hybrid PK-NRP. 
BLASTp analysis also retrieved two putative transporters, both identified as 
Drug:H+ Antiporter family 2 (DHA2) (SNA06273 and SNA06279). They are transporters of the 
Major Facilitator Superfamily (MFS) involved in multidrug resistance (MDR). The DHA2 family 
members were found to participate in the export of structurally and functionally unrelated 
compounds or to be involved in the uptake of amino acids (Dias and Sa-Correia, 2013). Thus, it 
is possible that both SNA06273 and SNA06279 are involved in the biosynthetic pathway of this 
hybrid compound either for its secretion or for the uptake of amino acids required for its 
biosynthesis.  
Regarding putative CSR, eight putative transcription regulators were detected, out of 
which three are likely to be transcription activators: SNA06240 (LysR-family), SNA06245 (AfsR-
family) and SNA06246 (LuxR-family). The remaining regulators, three are regulators whose 
function is predicted to be negative: SNA06239 (GntR-family), SNA06243 (AsnC-family), and 
SNA06274 (TetR-family). Furthermore, SNA06261 was identified as a serine/threonine protein 
kinase. 
SNA06231 and SNA06274 also code for putative regulatory proteins. However they were 
assumed to be out of the boundaries of S5C20 biosynthetic gene cluster. The relative distance 
to the core biosynthetic genes (20 kb and 13 kb, for SNA06231 and SNA06274, respectively) 
and the fact that these genes are surrounded by genes coding for putative hypothetical 
proteins or proteins not related with the production neither of a PK nor a NRP support this 
exclusion. 
3.1.6.2 Assessing the transcription of selected genes of S5C20 biosynthetic gene cluster 
The six putative regulatory encoding genes SNA06239, SNA06240, SNA06243, 
SNA06244, SNA06246 and SNA06261 from S5C20 were selected for transcription analysis 
together with the structural gene SNA06257 that codes for a putative mixed PKS-NRPS. 
Obtained results showed that SNA06257 was being poorly transcribed (Fig. 26) in both 
tested strains, which suggests that S5C20 is a silent cluster. 
Regarding the regulatory genes initially proposed as putative positive regulators 
(SNA06240, SNA06245 and SNA06246) only the LuxR-family SNA06246 presented low 
transcript levels, similarly to SNA06257. Therefore, it is likely to be responsible for the 
activation of S5C20 gene cluster and, consequently, it is the best candidate to be 
overexpressed. In turn, both SNA06240 and SNA06245 showed high transcription levels, 
especially in ΔpimM. 
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Figure 26 – Transcripton analysis of S5C20 selected genes by RT-PCR. Transcripts of SNA06257 (mixed PKS-NRPS 
encoding gene), SNA06239 (GntR-family encoding gene), SNA06240 (LysR-family encoding gene), 
SNA06243 (AsnC-family encoding gene), SNA06245 (AfsR-family encoding gene), SNA06246 (LuxR-
family encoding gene), SNA06261 (serine-threonine kinase encoding gene), 16S rRNA (positive control) 
and pimS1 (positive control for WT and negative control for ΔpimM) were analysed by RT-PCR with 30 
cycles on cDNA generated from RNA isolated at early stationary phase. Two biological replicates are 
shown for each strain. 
A curious trait in this cluster is the presence of genes encoding an AfsR-family regulator 
(SNA06245) and a serine-threonine kinase (SNA06261). In S. colicolor, AfsR (founding member 
of the AfsR-family) is a pleiotropic positive regulator involved in the production of secondary 
metabolites that is activated through the phosphorylation of specific residues catalysed by 
different kinases (Lee et al., 2002). Thus, it is possible that such a regulatory mechanism may 
be present in S5C20 cluster, making the overexpression of such genes, either alone or 
combined, a potential successful strategy for S5C20 activation. Finally, concerning the 
regulators SNA06239 (GntR-family) and SNA06243 (AsnC-family), both presented basal 
expression levels in both strains. These profiles suggest that both transcription regulators may 
act as transcription activators of the cluster, instead of negative CSR as predicted in the in silico 
analysis. It should be noted that GntR-family members are usually transcription repressors 
(Hillerich and Westpheling, 2006). Nevertheless, there are some reported cases for members 
of this family that act as positive regulators, e.g. PigT, which activates the transcription of the 
pigA–O operon in Serratia sp. ATCC 39006 (39006) (Fineran et al., 2005). 
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3.1.7 Conclusions 
The obtained results for the in silico analysis stress the need for manual curation of 
antiSMASH results. Only then it is possible to identify all the putative genes that are part of 
each biosynthetic gene cluster and to predict what is the role of the proteins that they encode 
for. Moreover, it is possible to validate or not antiSMASH characterization. For instance, S1C2 
is not a hybrid type II PK-terpene biosynthetic gene cluster, but two independent gene 
clusters, one coding for a type II PK (S1C2.1) and the other coding for a terpene (S1C2.2). 
It was also evident in the present analysis the difficulty to predict the regulatory 
functions of putative CSR. Although some of them are mainly related to a given function 
(either acting as activators or repressors) it is not guaranteed that they will behave that way. 
Furthermore, it was also difficult to obtain a precise prediction of the chemical structure 
of the end compound, although some shared high similarity and synteny with homologous 
gene clusters. As mentioned, putative tailoring genes have been identified within all presented 
biosynthetic gene cluster. Enzymes encoded by such genes should be able to functionalize the 
specialized metabolite. Nonetheless, S1C2.1 as holding a high synteny with the polyketide 
spore pigment biosynthetic gene cluster is likely to be responsible for the production of this 
compound in S. natalensis. 
Following the antiSMASH data curation and analysis, it was also important to assess the 
“silent” nature of the clusters. For that purpose the transcription of structural encoding genes 
(genes that code for proteins responsible for the assembly of the metabolite structural 
backbone) and putative transcription regulator(s) was determined by RT-PCR. The expression 
of the selected clusters was assessed not only in S. natalensis ATCC 27448 (wild-type), but also 
in S. natalensis ΔpimM, a strain that lacks pimaricin production (Anton et al., 2007). Worth 
noting that although not producing pimaricin, the precursors required for the synthesis of this 
metabolite should be available. 
From all the biosynthetic gene clusters submitted for transcriptional analysis, due to the 
time constraints, only three could be selected for the remaining tasks. S1C1 and S1C2.2, as 
they appeared to be not silenced, were not selected for overexpression. S1C2.1 although 
silenced was predicted to encode for the grey polyketide spore pigment which is already a 
widely studied product. Therefore, S1C2.1 was not selected for the remaining tasks. Leaving 
only four clusters, three were chosen to proceed with the project: S1C4, S1C5 and S5C20. The 
purpose of obtaining higher metabolic diversity was on the basis of this selection. 
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3.2 Ativating S. natalensis gene clusters 
As mentioned previously, manipulation of CSRs, either by overexpressing activators or 
deleting repressors, has proven to be a good strategy for increasing titres of secondary 
metabolite biosynthesis (Gottelt et al., 2010, Laureti et al., 2011, Scheffler et al., 2013). 
However, due to the time constraints, it was aimed to validate this activation strategy by 
overexpressing one typical positive regulator, since gene deletion in Streptomyces is still a 
time-consuming process. 
From cluster S1C4, SNA01173 that codes for a putative LuxR-family transcriptional 
regulator, has presented low transcription levels, in the same way as the studied structural 
gene. These results together with the fact that it is the only detected putative CSR justify why 
SNA01173 was selected to be overexpressed.  
Regarding the cluster S1C5, SNA01239 (MerR-family) was chosen for the following 
experiments. The fact that it is the only predicted transcription activator from S1C5 that was 
submitted for transcritption analysis together with its apparent basal transcription, similarly to 
the structural gene SNA01225, justifies its selection.  
Lastly, concerning S5C20, SNA06246 (LuxR-family) was the selected gene to be 
overexpressed. SNA06246 was only predicted positive transcription regulator from S5C20 
submitted for transcritption analysis that presented low transcription levels, as the structural 
gene SNA06257. 
3.2.1 Strategy 
To overexpress selected CSR, pIB139 plasmid was preferred as the expression vector 
(Wilkinson et al., 2002). pIB139 is an integrative vector that will allow cloning the selected 
regulatory genes under the control of the strong heterologous constitutive ermE*p of 
Saccharopolyspora erythraea. Resulting plasmids were integrated into the attB site of the 
chromosome of S. natalensis to create strains overexpressing the CSRs. In order to clone CSRs 
sequences into pIB139, they were first amplified by PCR, using chromosomal DNA from 
Streptomyces natalensis ATCC 27448 as template. The used primers (Table 1, Materials & 
methods) contained NdeI or EcoRV restriction sites. The resulting PCR products were cloned 
into the pGEM®-T Easy vector and sequenced at STAB VIDA. Validated strains were then used 
for plasmid recovery and enzymatic digestion, with NdeI and EcoRV. Finally, CSR genes were 
purified and cloned in pIB139. 
The obtained constructs, named pIBSNA01173, pIBSNA01239 and pIBSNA06246, were 
introduced into E. coli ET12567 [pUZ8002] before being transferred to S. natalensis ATCC 
27448 (wild-type) and S. natalensis ΔpimM by intergeneric conjugation. The strains S. 
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natalensis [pIBSNA01173], S. natalensis [pIBSNA01239], S. natalensis [pIBSNA06246], SNA 
ΔpimM [pIBSNA01173], S. natalensis ΔpimM [pIBSNA01239] and S. natalensis ΔpimM 
[pIBSNA06246] were generated. 
The empty pIB139 vector was also inserted into E. coli ET12567 [pUZ8002] and 
transferred then to S. natalensis ΔpimM strain. The resulting strain was used as control 
together with S. natalensis [pIB139] available at the laboratory. 
Figure 27 summarizes the applied strategy.  
 
Figure 27 – Schematic representation of the chosen approach for the overexpression of the selected genes in S. 
natalensis and S. natalensis ΔpimM. 
3.2.2 Exconjugants validation 
To confirm the presence of the genes of interest three different clones for each 
conjugation were submitted for PCR analysis, using genomic DNA as template. The different 
sets of primers consisted in one that hybridises within the plasmid and another that hybridises 
in the gene pretended to be overexpressed. This way, it was possible to ascertain the presence 
of the construct within the genome of the strain. 
Results of the PCR analysis are displayed in Figure 28. All the presented strains were 
validated since their amplicons matched their expected size (Table 3). 
Table 3 – Expected sizes of the amplicons of the different S. natalensis (SNA) strains. 
Strain Primer pair 
Expected size of 
the amplicon (bp) 
SNA ΔpimM [pIB139] pIB_U_F and pIB_U_R 293 
SNA [pIBSNA01173] and SNA 
ΔpimM [pIBSNA01173] 
pIB_U_F and S1C4R1_AS 400 
SNA [pIBSNA01239] and SNA 
ΔpimM [pIBSNA01239] 
pIB_U_F and S1C5R2_AS 491 
SNA [pIBSNA06246] and SNA 
ΔpimM [pIBSNA06246] 
pIB_U_F and S5C20R4_AS 541 
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Figure 28 – PCR validation of exconjugants. Three exconjugants were randomly selected (lanes 1, 2 and 3) for each 
conjugation: A and E – pIBSNA01173; B and F – pIBSNA01239; C and G – pIBSNA06246; D – pIB139. 
Plasmid DNA was used as control (lane C) and Gene Ruler (Thermo Scientific; #SM0331) was used as 
molecular-weight size marker (M). 
Additionally, three clones for each conjugation already validated by PCR were also 
validated by for Southern blotting analysis (Fig. 29-32). Internal fragments of the studied genes 
(SNA01173, SNA01239 and SNA06246) or of the pIB139 plasmid were used as probes. 
Restriction enzymes were selected in a way to obtain a digested fragment that should include 
part of the surrounding region of pIB139 (and derivative constructs) integration sites at the 
A B 
D E 
F 
G 
C 
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chromosome (attB) together with the probes hybridization sites. Since unspecific bands of 
plasmid pSNA1 can be detected, its restriction fragments were also taken into consideration 
(Table 4). 
Table 4 – Expected sizes for southern hybridization bands of the different S. natalensis (SNA) strains. (WT, wild-type; 
NA, not applicable). 
Target 
Used restriction 
enzyme(s) 
Strain 
Expected size of the 
gDNA bands (bp) 
Expected size 
of pSNA1 
bands (bp) 
pIB139 BglII 
SNA WT and SNA ΔpimM NA 
5969; 3398 SNA [pIB139] and SNA 
ΔpimM [pIB139] 
11517 
SNA01173 EcoRV and KpnI 
SNA WT and SNA ΔpimM 8671 
3677; 3464; 
1222; 1004 
SNA [pIBSNA01173] and 
SNA ΔpimM 
[pIBSNA01173] 
7585 
SNA01239 AgeI and NotI 
SNA WT and SNA ΔpimM 4409 3074; 1584; 
1563; 885; 
827; 781; 437; 
153; 45; 15 
SNA [pIBSNA01239] and 
SNA ΔpimM 
[pIBSNA01239] 
7813 
SNA06246 NcoI 
SNA WT and SNA ΔpimM 7962 
9128; 239 SNA [pIBSNA06246] and 
SNA ΔpimM 
[pIBSNA06246] 
6475 
S. natalensis [pIB139], S. natalensis [pIBSNA01173] exconjugant #8, S. natalensis 
[pIBSNA01239] exconjugant #3, S. natalensis [pIBSNA06246] exconjugant #7, S. natalensis 
ΔpimM [pIB139] exconjugant #4, S. natalensis ΔpimM [pIBSNA01173] exconjugant #11, S. 
natalensis ΔpimM [pIBSNA01239] exconjugant #3, S. natalensis ΔpimM [pIBSNA06246] 
exconjugant #1 were selected for the remaining experiments. These strains are named, from 
here on, without the cardinal and associated number, as representatives of each conjugation. 
3.2.3 Transcription analysis of the exconjugants  
Due to time constraints, transcription analyses were performed using S. natalensis wild-
type and derived exconjugation strains. Two biological replicates of each strain were used in 
order to ensure the liability of the results, with the exception for S. natalensis [pIB139] due to 
technical issues. 
Obtained results are similar between S1C5 and S5C20 biosynthetic gene clusters: the 
CSR chosen to be overexpressed showed increased levels when compared with the control 
strains (Fig. 33 and 34). However, the studied structural gene did not presented any increased 
level between the exconjugants and control strains. 
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Figure 29 – Southern blot confirmation of strains S. natalensis [pIB139] and S. natelensis ΔpimM [pIB139] genetic 
identity. A). BglII restriction pattern for the predicted pIB139 integration (shown in a blue box). The 
probe used for Southern hybridisation is indicated by the orange line. B). Southern blot hybridization of 
digested Streptomyces exconjugants genomic DNA by making use of dioxygenin labelled probes. λ 
HindIII (Thermo Scientific; #SM0102) was used as molecular-weight size marker (M). Lane 1 – S. 
natalensis; 2 - S. natalensis [pIB139]; 3 - S. natalensis ΔpimM; 4 – S. natalensis ΔpimM [pIB139] 
exconjugant #3; 5 – S. natalensis ΔpimM [pIB139] exconjugant #4; 6 – S. natalensis ΔpimM [pIB139] 
exconjugant #5. 
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B 
Page 58 
pIBSNA01173 
 
Wild-type 
 
pIBSNA01173 plasmid integration 
 
 
Figure 30 – Southern blot confirmation of strains S. natalensis [pIBSNA01173] and S. natelensis ΔpimM 
[pIBSNA01173] genetic identity. A). EcoRV and KpnI restriction pattern for the predicted 
pIBSNA01173 integration (shown in a blue box). The CSR gene SNA01173 is represented by a green 
arrow. The probe used for Southern hybridisation is indicated by the orange line. B). Southern blot 
hybridization of digested Streptomyces exconjugants genomic DNA by making use of dioxygenin 
labelled probes. λ HindIII (Thermo Scientific; #SM0102) was used as molecular-weight size marker 
(M). Lane 1 – S. natalensis; 2 - S. natalensis [pIBSNA01173] exconjugant #8; 3 - S. natalensis 
[pIBSNA01173] exconjugant #9; 2 - S. natalensis [pIBSNA01173] exconjugant #10; 5 - S. natalensis 
ΔpimM; 6 – S. natalensis ΔpimM [pIBSNA01173] exconjugant #5; 7 – S. natalensis ΔpimM 
[pIBSNA01173] #6; 8 – S. natalensis ΔpimM [pIBSNA01173] exconjugant #11. P – Unspecific band 
from the plasmid pSNA1. 
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Figure 31 – Southern blott confirmation of strains S. natalensis [pIBSNA01239] and S. natelensis ΔpimM 
[pIBSNA01239] genetic identity. A). AgeI and NotI restriction pattern for the predicted pIBSNA01239 
integration (shown in a blue box). The CSR gene SNA01239 is represented by a green arrow. The 
probe used for Southern hybridisation is indicated by the orange line. B). Southern blot hybridization 
of digested Streptomyces exconjugants genomic DNA by making use of dioxygenin labelled probes. λ 
HindIII (Thermo Scientific; #SM0102) was used as molecular-weight size marker (M). Lane 1 – S. 
natalensis; 2 - S. natalensis [pIBSNA01239] exconjugant #2; 3 - S. natalensis [pIBSNA01239] 
exconjugant #3; 2 - S. natalensis [pIBSNA01239] exconjugant #9; 5 - S. natalensis ΔpimM; 6 – S. 
natalensis ΔpimM [pIBSNA01239] exconjugant #6; 7 – S. natalensis ΔpimM [pIBSNA01239] 
exconjugant #3; 8 – S. natalensis ΔpimM [pIBSNA01239] exconjugant #5. P – Unspecific band from 
the plasmid pSNA1. 
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Figure 32 – Southern blott confirmation of strains S. natalensis [pIBSNA06246] and S. natelensis ΔpimM 
[pIBSNA06246] genetic identity. A). AgeI and NotI restriction pattern for the predicted pIBSNA01239 
integration (shown in a blue box). The CSR gene SNA06246 is represented by a green arrow. The 
probe used for Southern hybridisation is indicated by the orange line. B). Southern blot hybridization 
of digested Streptomyces exconjugants genomic DNA by making use of dioxygenin labelled probes. λ 
HindIII (Thermo Scientific; #SM0102) was used as molecular-weight size marker (M). Lane 1 – S. 
natalensis; 2 - S. natalensis [pIBSNA06246] exconjugant #5; 3 - S. natalensis [pIBSNA06246] 
exconjugant #7; 2 - S. natalensis [pIBSNA006246] exconjugant #17; 5 - S. natalensis ΔpimM; 6 – S. 
natalensis ΔpimM [pIBSNA06246] exconjugant #1; 7 – S. natalensis ΔpimM [pIBSNA06246] 
exconjugant #5; 8 – S. natalensis ΔpimM [pIBSNA06246] exconjugant #8. P – Unspecific band from 
the plasmid pSNA1. 
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Figure 33 – Transcription analysis of S1C5 selected genes by RT-PCR. Transcripts of SNA01225 (NRPS encoding 
gene), SNA01232 (TetR-family encoding gene), SNA01239 (MerR-family encoding gene), SNA01250 
(DeoR-family encoding gene), SNA01254 (PaaX-family encoding gene), SNA01256 (TetR-family 
encoding gene), SNA01258 (TetR-family encoding gene), 16S rRNA (positive control) and pimS1 
(positive control for WT and negative control for ΔpimM) were analysed by RT-PCR with 30 cycles on 
cDNA generated from RNA isolated at early stationary phase. Two biological replicates are shown for 
WT and [pIBSNA01239]. 
 
Figure 34 – Transcripton analysis of S5C20 selected genes by RT-PCR. Transcripts of SNA06257 (mixed PKS-NRPS 
encoding gene), SNA06239 (GntR-family encoding gene), SNA06240 (LysR-family encoding gene), 
SNA06243 (AsnC-family encoding gene), SNA06245 (AfsR-family encoding gene), SNA06246 (LuxR-
family encoding gene), SNA06261 (serine-threonine kinase encoding gene), 16S rRNA (positive control) 
and pimS1 (positive control for WT and negative control for ΔpimM) were analysed by RT-PCR with 30 
cycles on cDNA generated from RNA isolated at early stationary phase. Two biological replicates are 
shown for WT and [pIBSNA06246]. 
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The gene expression analysis indicates that the CSR overexpression was successful 
although apparently the expression of structural genes was not activated. The results suggest 
that these clusters might have additional layers of regulation beyond the selected genes. 
Worth to note that secondary metabolism gene clusters often possess more than a 
single associated CSR, wherein one of the CSR is an ultimate regulator of antibiotic production, 
while others may act either singularly on the ultimate regulatory gene, or pleiotropically on 
unrelated and unlinked genes (Makitrynskyy et al., 2013). Thus, it is possible that there are 
regulatory cascades controlling the activation of the biosynthetic gene clusters. By way of 
example, in S. coelicolor, the cryptic polyketide (CPK) biosynthesis depends upon the cpkO 
activation. Conversely, the activation of the cpk cluster also involves, among other regulatory 
molecules, the protein ScbR, coded by scrB, and gamma-butyrolactone congeners (SCB) coded 
by scbA. On the one hand, ScbR binds to cpkO promoter region, preventing its transcription. 
On the other hand, SCB is able to bind to ScbR, sequestering all ScbR free proteins and 
releasing cpkO from repression (Liu et al., 2013).  
This way, it is conceivable that SNA01239 and SNA06246 are only part of a regulatory 
cascade in which other negative CSR, or even some other pleiotropic regulators located 
outside the cluster, are preventing them from activating the structural genes. 
As mentioned in the introduction there are nutrient-sensing regulators already ascribed 
to have a role in the antibiotic production in S. coelicolor. Indeed, phenomena like carbon 
catabolite repression may have counteracted the effect of the overexpression of these CSRs. 
Moreover, the media may lack an important co-factor needed for the transcription regulators 
to acquire the DNA binding conformation (Thomas and Chiang, 2006).  
Lastly, SNA01239 and SNA06246 may not be positive regulators, but be negative 
instead. Either the MerR-family (Brown et al., 2003) or the LuxR-family (Chen and Xie, 2011) 
have been reported to have negative transcription regulators as members. 
In the case of S1C4, the putatively overexpressed gene (SNA01173) shows apparent 
similar expression levels as the controls (Fig. 35). Such results are inconsistent with the ones 
obtained for the first transcription analysis, in which SNA01173 showed low transcription 
levels (Fig. 18). That could be due to the fact that SNA01173 holds a different transcription 
pattern along S. natalensis growth. Nieselt and co-workers have already shown that genes 
composing different biosynthetic clusters have their own transcription patterns, in which the 
expression varies along time (Nieselt et al., 2010). Thus, in spite of all mycelium samples were 
harvested at the beginning of the stationary phase, it may have happened that they were in 
slightly different growth phase stages. Moreover, as already mentioned in this work, 
bacteriocins are all produced during the primary phase of growth, though antibiotics are 
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usually secondary metabolites (Beasley and Saris, 2004). This fact emphasises the difference 
that can be seen in gene transcription patterns when samples are collected at different stages 
of growth. Furthermore, the overexpression of the gene, which is not evident in the RT-PCR 
results, did not allow the activation of the studied structural gene. Similarly to the other 
clusters it could be (1) due to the effect of CSR or other pleiotropic regulators acting as 
repressors, (2) to the lack of a cofactor, (3) to the used media or (4) SNA01173 acts as a 
negative regulator instead. Regarding the latter point, it should be noted that there are 
secondary metabolite biosynthetic gene clusters with no associated CSR, namely moenomycin 
(Ostash et al., 2007). 
 
Figure 35 – Transcription analysis of S1C4 selected genes by RT-PCR. Transcripts of SNA01166 (TAP encoding gene), 
SNA01173 (LuxR-family encoding gene) and 16S rRNA (positive control) were analysed by RT-PCR with 
30 cycles on cDNA generated from RNA isolated at early stationary phase. Two biological replicates are 
shown for WT and [pIBSNA01173]. 
In addition to the mentioned four reasons, it should be mentioned that, unlike S1C5 and 
S5C20 studied structural genes, it might be possible that SNA01166 is not involved in the 
biosynthesis of the end bacteriocin. One other protease, potentially coded by a predicted 
hypothetical protein, might be the one responsible for the cleavage of the N terminal of the 
pre-peptide. 
3.2.4 Comparative metabolomics 
3.2.4.1 Bioassay experiments 
Despite the fact that the activation of the expression of the studied genes was 
apparently not achieved, all new developed strains were submitted for a preliminary 
comparative metabolic profile. 250 µL of culture broth was concentrated and tested against a 
panel of test organisms that includes reference strains of Gram-positive bacteria (Bacillus 
cereus, Staphylococcus aureaus and Enterococcus faecalis), Gram-negative bacteria 
(Escherichia coli) and yeast (Saccharomyces cerevisiae). 
No inhibition halos were detected in the bioassays performed with any of the tested 
Gram-positive bacteria and Gram-positive negative bacteria. This could mean that none of the 
S. natalensis strains produce any metabolite capable of killing these microorganisms or 
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suppressing their growth. Otherwise, the used amount of media supernatant does not contain 
the minimum concentration of the putative product so it can work as an inhibitory agent.  
Regarding bioassays performed with Saccharomyces cerevisiae as test organism it is 
possible to notice the presence of inhibition halos surround the area with media supernatant 
from S. natalensis wild-type and derivative strains (Fig. 36). S. natalensis produces pimaricin, 
na antifungal that inhibits the growth of the yeast S. cerevisiae, hence the inhibition halos. The 
measurement of inhibition halos revealed differences between the applied supernatants. 
pIB139 vector incorporation appears to slightly decrease the production of the metabolite(s) 
responsible for the inhibition zone. Moreover, while no differences were detected between 
the halos from S. natalensis [pIB139] and S. natalensis [pIBSNA06246], S. natalensis 
[pIBSNA01239] culture broth led to lower inhibition halos. These results suggest different 
production titers of pimaricin. 
    
 
Figure 36 – Bioassay results for the collected culture medium, using Saccharomyces cerevisiae as test organism. A). 
Plate showing antibacterial activity of S. natalensis and developed exconjugants broth cultures by agar 
well diffusion method. B). Graphical representation of the inhibition halos. Results show the average 
obtained among two technical replicates of two independent biological replicates. Vertical bars indicate 
standard deviation of the mean values. The differences between exconjugants S. natalensis 
[pIBSNA01239] or S. natalensis [pIBSNA01239] and S. natalensis [pIB139] samples were assessed by 
independent t-test. (*, P < 0.05). 
Contrasting with the latter results, no inhibition zones were visualized in the bioassays 
performed with supernatants collected from culture broth of S. natalensis ΔpimM and 
derivative strains that do not produce pimaricin (data not shown). Altogether, bioassay results 
with Saccharomyces cerevisiae as test organism suggest that pimaricin is the compound that is 
A 
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supressing the yeast growth and no other inhibitory agent is being produced as the result of 
overexpressing SNA06246, SNA01239 and SNA01173. Nevertheless, these results do not 
represent quantitative data. 
3.2.4.2 HPLC experiments 
In order to clarify the previous results and look for possible new products that can be 
produced by the developed exconjugants to which the tested microorganisms are not sensible, 
culture broth methanolic extracts were analysed by HPLC. 
The resulting diode array spectra for all strains are displayed in Appendix II. Analysis of 
the wild-type extract at 304 nm revealed a main peak with a retention time (RT) of 13.85 min 
(peak #1, Fig. 37). This peak had the same RT as the pimaricin standard and displayed the 
typical absorption spectrum of pimaricin with three characteristic absorption maximums (290, 
304 and 319 nm). A second peak, with a RT of 16.6 min also displayed a tetraene typical 
absorption spectrum (peak #2, Fig. 37). This peak displayed an additional absorption peak at 
260 nm that suggests the presence of a conjugated double bond at C2-C3 and C4-C5 in the 
pimaricin backbone (Mendes et al., 2005). The introduction of the epoxy group by the P450 
monooxygenase into the pimaricin module at C4-C5 is the last step of pimaricin biosynthesis 
(Mendes et al., 2005) (Fig. 38). Therefore, the presence of peaks displaying an additional 
absorption maximum at 260 nm suggests the presence of pimaricin precursor in the wild-type 
culture broth. 
 
Figure 37 – HPLC chromatogram at 304 nm of S. natalensis culture broth extracts. 1). Pimaricin peak spectra. 2). 
Putative pimaricin precursor. Arrows indicate peaks corresponding absorption spectra. 
Nevertheless, the main differences were detected at 400 nm between the different 
wild-type derivative exconjugants (Fig. 39-41).  
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Figure 38 – Last step for pimaricin biosynthesis: de-epoxypimaricin conversation into pimaricin, catalysed by PimD 
[Adapted from Mendes et al., 2005]. 
The first difference refers to different intensities of two retention peaks among the 
analysed strains: peak #3 (RT of 14.2 min) and peak #5 (RT of 18.9 min). These peaks were both 
increased in strains S. natalensis [pIBSNA016246] and S. natalensis [pIBSNA01173] and are not 
present in S. natalensis [pIBSNA01239] when compared to the control strain (S. natalensis 
[pIB139]). The peak area was normalized against the culture dry weight in order to be able to 
perform a comparative analysis (Fig. 42). Peak #3 had an 11.3 and 5.3 fold increase in strains S. 
natalensis [pIBSNA01173] and S. natalensis [pIBSNA06246], respectively. The increase in peak 
#5 was not as pronounced as peak #3, although it led to 1.85 and 1.84 fold increase in strains 
S. natalensis [pIBSNA01173] and S. natalensis [pIBSNA06246], respectively. 
The second main difference between the analysed strains was the presence of three 
new retention peaks at 400 nm: peak #4 (RT of 17.5 min), peak #6 (RT of 13.2 min) and peak #7 
(RT of 13.3 min). Peaks #4 and #6 are present in the culture broth of strains S. natalensis 
[pIBSNA01239] and S. natalensis [pIBSNA01173]. Strain S. natalensis [pIBSNA06246] displayed 
small peak at the corresponding RT. Finally peak #7 was present exclusively in strain S. 
natalensis [pIBSNA01173]. 
Worth note that the absorption spectra of all peaks had similar absorption maximums, 
ranging from 402 to 406 nm. Additionally the absorption spectra of peak #6 and #7 displayed 
typical pimaricin spectra. This is due to the proximity of pimaricin or its precursors/by-products 
RT. 
Concerning ΔpimM and derivative strains, no differences were detected between them 
(Fig. 43-45). Nonetheless, it is interesting to observe that none of the new obtained spectra 
displayed the pimaricin typical spectrum between 250 and 350 nm. These results reinforce the 
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assertion that of both #6 and #7 in wild-type derivative strains consist in a mixture of two 
independent spectra. As absorption spectra were similar peaks with same RT they were named 
equally. 
 
Figure 39 – HPLC chromatogram at 400 nm of S. natalensis [pIBSNA06246] (black line) and S. natalensis [pIB139] 
(dashed grey line) culture broth extracts. Arrows indicate peaks corresponding absorption spectra. 
 
Figure 40 – HPLC chromatogram at 400 nm of S. natalensis [pIBSNA01239] (black line) and S. natalensis [pIB139] 
(dashed grey line) culture broth extracts. Arrows indicate peaks corresponding absorption spectra. 
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Figure 41 – HPLC chromatogram at 400 nm of S. natalensis [pIBSNA01173] (black line) and S. natalensis [pIB139] 
(dashed grey line) culture broth extracts. Arrows indicate peaks corresponding absorption spectra. 
 
Figure 42 – Peak areas per dry weight (mg) ratios identified in HPLC chromatograms at 400 nm. 
Moreover, it is also thought-provoking that peaks #4, #6 and #7 that are not present 
neither in the wild-type strain nor in S. natalensis [pIB139], are present in all ΔpimM strains 
chromatograms. This fact points that the silencing of a biosynthetic gene cluster does alter the 
metabolic profiling of a strain. Moreover, these results also support the idea that that the 
silencing of one gene cluster putatively sets free metabolic precursors essential for the 
production of other specialized metabolites. 
Lastly, it should be mentioned that analysis at 304 nm also allowed to quantify 
differences in the pimaricin production between S. natalensis wild-type and derived strains 
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(Fig. 46). Results showed no differences between the wild-type strain and S. natalensis 
[pIB139], pointing that pIB139 vector integration did not affect the pimaricin production. 
Regarding the remaining exconjugants it is possible to ascertain that S. natalensis 
[pIBSNA06246] and S. natalensis [pIBSNA01239] showed decreased volumetric and specific 
pimaricin production values when compared with S. natalensis [pIB139]. In fact, S. natalensis 
[pIBSNA01239] presented significant decreases of 3.28 and 2.34 fold in volumetric and specific 
pimaricin production, respectively, when compared with S. natalensis [pIB139]. In turn, S. 
natalensis [pIBSNA01173] presented increased volumetric and specific pimaricin production 
values of 1.88 and 1.70 fold, respectively. The latter results, together with the ones obtained 
for S. natalensis [pIBSNA01173] bioassays (in which this strain exhibited larger inhibition halos 
than the control one) suggested that the overexpressed LuxR protein it is exerting a pleiotropic 
effect, modulating the pimaricin biosynthetic gene cluster. However, the results obtained for S. 
natalensis ΔpimM derivative strains (no pimaricin peak) showed that SNA01173 
overexpression is not sufficient to bypass the absence of the pimaricin CSR PimM. 
Summarising, the results obtained among all the strains point that they have different 
metabolic patterns. Two new peaks (#4 and #6) were detected in all S. natalensis strains 
overexpressing the different CSRs. Additionally S. natalensis [pIBSNA01173] appears to be 
overproducing pimaricin and the product corresponding to peak #7. In turn, S. natalensis 
[pIBSNA01239] underproduces pimaricin and does not even produce the compound related to 
peaks #3 and #5 present in the control strain. This way, S. natalensis [pIBSNA01239] could be 
deviating metabolic precursors for the production of a novel compound. S. natalensis 
[pIBSNA06246] was the new exconjugate with the most similar metabolic profile as S. 
natalensis [pIB139], the control strain. Lastly, no differences were detected between ΔpimM 
and derivative strains, although all have appeared to be producing the products that were not 
detected in the wild-type, S. natalensis [pIB139] or S. natalensis [pIBSNA01239]. Worth to note 
that all the similar absorption spectra suggest that the novel peaks could be by-products of 
one compound. 
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Figure 43 – HPLC chromatogram at 400 nm of S. natalensis ΔpimM [pIBSNA06246] (black line) and S. natalensis 
[pIB139] (dashed grey line) culture broth extracts. Arrows indicate peaks corresponding absorption 
spectra. 
 
Figure 44 – HPLC chromatogram at 400 nm of S. natalensis ΔpimM [pIBSNA01239] (black line) and S. natalensis 
[pIB139] (dashed grey line) culture broth extracts. Arrows indicate peaks corresponding absorption 
spectra. 
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Figure 45 – HPLC chromatogram at 400 nm of S. natalensis ΔpimM [pIBSNA01173] (black line) and S. natalensis 
[pIB139] (dashed grey line) culture broth extracts. Arrows indicate peaks corresponding absorption 
spectra. 
Figure 46 – Pimaricin production. A). Volumetric production. B). Specific production. The graphical results show the 
average obtained among two technical replicates of two independent biological replicates. Vertical 
bars indicate standard deviation of the mean values. The differences between exconjugants S. 
natalensis [pIBSNA01239] or S. natalensis [pIBSNA01239] samples and S. natalensis [pIB139] samples 
were assessed by independent t-test. (*, P < 0.001; **, P < 0.05). 
3.2.5 Conclusions 
The delineated strategy for overexpressing three biosynthetic gene clusters, by 
modulating the transcription of one of its putative positive CSR, was apparently not achieved 
with any of the selected ones. Laureti and its co-workers applied a similar strategy for the 
activation of a type I PKS from Streptomyces ambofaciens ATCC 23877 (Laureti et al., 2011). 
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Though, all putative positive CSR encoding genes were overexpressed, instead of only one of 
them. From the three overexpressed genes, one led to the activation of the biosynthetic gene 
cluster. Thus, these data suggests that it should still be interesting to overexpress other CSR 
from the selected biosynthetic gene clusters S1C5 and S5C20, in order to activate these 
genomic regions.  
For S1C4, as it does not hold any other regulator, this strategy could not be possible. 
Nevertheless, it could still be interesting to study the transcription state of one other S1C4 
structural gene, since it cannot be ascertained that SNA01166 is involved in the biosynthesis of 
the bacteriocin. Moreover, it is known that the regulation of the biosynthesis of bacteriocins 
from Gram-positive bacteria relies on signal transduction systems. These compounds can be 
auto-regulated, in which bacteriocins activate their own expression, by interacting with a 
membrane-bound histidine protein kinase. Then, the internal portion of the kinase transfers a 
phosphoryl group to the second component, a response regulator located in the cellular 
cytoplasm. This causes a change in the structure of the response regulator which activates 
transcription. On the other hand, instead of autoregulation, a peptide pheromone induction is 
the one responsible for the expression of the bacteriocin. A gene unique from the structural 
gene encodes a bacteriocin-like substance which is the signal recognized by the extracellular 
domain of the histidine protein kinase (Snyder and Worobo, 2014). Since SNA01173 protein 
domain analysis revealed the presence of a signal receiver domain, that receives the signal 
from the sensor partner in a two-component system (aa 1-112), together with a C-terminal 
DNA-binding domain of LuxR-like proteins (aa 138-194), it is, in fact, likely to be the bacteriocin 
transcription activator. 
Still in regard of S1C4 it is also important to mention that results did not show clearly 
that the studied SNA01173 is being overexpressed in the S. natalensis [pIBSNA01173] 
replicates. RNA samples collected from S. natalensis [pIBSNA01173], S. natalensis wild-type 
and S. natalensis [pIB139] should be submitted for quantitative RT-PCR (RT-qPCR) in order to 
clarify the latter results. 
Concerning metabolic profiles, two strains stood out: S. natalensis [pIBSNA01173] and S. 
natalensis [pIBSNA01239]. 
S. natalensis [pIBSNA01173] appears to have increased the production of the 
compounds represented by the chromatogram peaks #3 and #5, when compared to the 
control S. natalensis [pIB139] strain. Additionally, three novel peaks, not present in either wild-
type or [pIB139] strain were also detected: #4, #6 and #7. Besides, S. natalensis [pIBSNA01173] 
showed significant increased levels of pimaricin specific production, when compared to S. 
natalensis [pIB139]. In fact, it has even reached a specific production 1.70 times higher than 
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the wild-type. This result, suggests that SNA01173 is being overexpressed and, as it is a 
regulator from the same family as PimM (LuxR-family), this putative CSR could be exerting a 
pleiotropic effect and acting specifically in the pimaricin gene cluster. Therefore, the alignment 
of amino acid sequences of these two proteins was performed and revealed partial identity 
between the helix-turn-helix (HTH) regions. Similarities between both DNA binding domains 
could suggest similar recognized DNA binding motifs. However, the identity between these 
two regions is low (30%). This fact, together with no detection of pimaricin in the ΔpimM 
[pIBSNA01173] strain, can explain the fact that SNA01173 could not activate pimaricin 
production in ΔpimM. Furthermore, these data suggests a pleiotropic role for SNA01173, 
acting on genes unrelated and unlinked with the S1C4,including the pimaricin biosynthetics 
gene cluster. 
In turn, it is also interesting to note that HPLC chromatogram at 400 nm of S. natalensis 
[pIBSNA01239] did not present the two peaks displayed in the control chromatogram (peaks 
#3 and #5). That could be due to the fact it is diverting precursors essential for the production 
of these metabolites, in order to produce a new one. Furthermore, S. natalensis 
[pIBSNA01239] presented a significant decrease in pimaricin specific production of 3.28 fold 
when compared to the control. This result is coherent with the low inhibition halos detected in 
the performed bioassay experiments. Worth to note that, as putative MerR-family protein, it is 
likely that SNA01239 acts as a transcription activator. However, it may act as a negative (and 
pleiotropic) regulator instead. 
It is important to mention that the peaks regarding the 400 nm HPLC chromatograms 
appear to be by-products of the same compound due to the similarities among absorption 
spectra. It is not possible to know exactly which one is the end product and whose are the by-
products. Therefore, it can be said that it was not detected new product in neither S. 
natalensis [pIBSNA01239], S. natalensis [pIBSNA06246] nor S. natalensis [pIBSNA01173], but 
only different by-products. Nevertheless, it does not ensure that new products are not being 
produce. Those compounds might be covered by exhibiting peaks, namely the first ones that 
are associated to culture medium leftovers. Additionally the selected extraction and HPLC 
methods could not the appropriated ones for its detection. Thus, further extraction and HPLC 
approaches must be performed in order to (1) gain better insights about the metabolic profile 
of all the developed strains and to (2) check if they whether or not produce novel bioactive 
compounds.
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4. Concluding remarks and future perspectives 
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The slowdown of antimicrobial drug discovery and development, together with the 
continuous increase of the antimicrobial resistance phenomenon, outstands the need for 
novel bioactive compounds. Classical screening methods for those products have been 
outdated and suffer from high costs than often lead to high rediscovery rates. On the contrary, 
the development of high throughput technology for the screening of biological activities 
together with the molecular awakening of “silent” clusters may allow the unleash of secondary 
metabolism potential hide in the genome sequence. Additionally, synthetic biology defined as 
the design and construction of biological devices and systems for useful purposes (Schmidt, 
2012) will also have a word to say in the discovery of novel bioactive compounds. 
In this project, it was aimed to activate the transcription of specialized metabolite 
biosynthetic gene clusters. The activation of what is known as “silent” clusters is a promising 
approach to unveil novel biologically active compounds that could be further developed into 
hit compounds to feed the drug discovery pipeline (Olano et al., 2014).  
The genome mining combined with the positive CSR overexpression stands as an already 
proved successful and straightforward strategy for the activation of those gene clusters 
(Laureti et al., 2011, Gottelt et al., 2010). This approach was applied in the present work, by 
performing an in-depth in silico S. natalensis genome mining analysis and selecting three 
putative positive CSR from three independent studied silent gene clusters for overexpression. 
S. natalensis ΔpimM, a pimaricin non-producing strain, was also teste due to the expected 
precursors bioavailability resulting of no pimaricin production. 
However, the gene expression results suggest that the activation of such biosynthetic 
gene clusters was not achieved. Several reasons may justify the latter, namely the effect of 
negative CSR or pleiotropic regulators, the lack of a co-factor, essential for the interaction 
between DNA promoter zones and the regulators, the used media or being the selected genes 
to act as a negative regulator s. In the particular case of S1C4 it is also conceivable that the 
structural gene subjected for transcription analysis does not code for a protein involved in the 
biosynthesis of the end product. 
Nevertheless, all strains were subjected for comparative metabolic profiling analysis and 
interesting results were obtained with the wild-type derived strains.  
The HPLC chromatograms analysis at 400 nm of S. natalensis [pIBSNA01173], a strain 
putatively overexpressing the LuxR protein encoding gene SNA01173 from S1C4, unveiled the 
presence of three peaks that were not detected neither in the wild-type nor in S. natalensis 
[pIB139] strains: #4, #6 and #7. Furthermore, other two presented higher peak area per dry 
weight when compared to the control S. natalensis [pIB139] strain: #3 and #5. Still in regard of 
S. natalensis [pIBSNA01173] metabolic profile, this strain presented a significant increase in 
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pimaricin production. In fact, results pointed a specific production of this metabolite 
approximately 1.74 times higher than the wild-type strain. Therefore, SNA01173 could be 
involved in the activation of pimaricin biosynthetic gene cluster  
Remarkable results have been also been achieved for S. natalensis [pIBSNA01239]. The 
HPLC chromatogram at 400 nm of this strain, that is overexpressing the MerR protein encoding 
gene SNA01239 from S1C5, showed the disappearance of two peaks that were present in the 
wild-type and the in S. natalensis [pIB139] strains (peaks #3 and #5). Additionally, it presented 
significant decrease in the pimaricin specific production. This could mean that this strain is 
diverting the pimaricin metabolic precursors for the production of one other product. 
As stated earlier, the performed extraction and HPLC methods were specially designed 
for pimaricin analysis. Therefore, it is possible that novel bioactive compounds are being 
produced by the new developed strains, although they were not detected by the performed 
experiments. This way, it is of great importance to perform different extraction and HPLC 
methods in order to look for the possible new products in a near future. By way of example, a 
new method of extraction could that could allow to test the whole culture broth (25 mL) 
instead of only 500 μL may allow the detection of compounds produced in low amounts. Using 
other solvents (including polar solvents, in opposition to methanol) should also be tested 
since the new compounds may have higher affinity to them. 
Concerning the HPLC future studies, it should also be experimented to perform 
chromatography tests with other columns, solutions for the mobile phase and elution methods 
should. For example, achieve a lower percentage of the used solvent under a lower flow rate 
and for a longer period of time may allow unmasking certain compounds. Furthermore, in 
order to identify the compounds that are being produced, HPLC experiments should be 
repeated, but coupled to a mass spectrometer (MS) and a nuclear magnetic resonance (NMR) 
spectroscopy. 
Carrying out new bioassay experiments using the multi-drug resistant Gram-negative 
bacteria Klebsiella pneumonia, Acinetobacter baumannii and Pseudomonas aeruginosa, as red-
flagged antimicrobial priority targets (European Centre for Disease Prevention and Control, 
2009, 2013), should also be performed. As stated, comparative metabolic profiling results 
suggest that new products might being produced, or, at least, some are being overproduced. 
Therefore, they may hold bioactive characteristics that could help fighting antibiotic 
resistance. Moreover, since cancer is a major burden of disease worldwide, accounting for 8.2 
million deaths only in 2012 (Ferlay et al, 2013), and since anticancer compounds have already 
been isolated from Streptomyces culture (e.g. doxorubicin) it should be interesting to perform 
bioassays using different cancer line cells. 
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Once concluded the metabolic profiling of all new developed strains there are other 
possible future studies also of great importance. For instance, a transcription analysis 
throughout the growth curve instead of only at one point. This way it should be possible to get 
a better understanding of what genes are silenced or being expressed. Regarding S1C4 
biosynthetic gene cluster, RT-qPCR may be firstly performed in order to ensure the 
overexpression of the putative CSR (not confirmed by the carried out RT-PCR experiments). 
Still in regard of S1C4, if in the latter experiments SNA01166 did not show to be expressed in 
the strains putatively overexpressing SNA01173, one other putative structural gene should be 
selected. This way it can be ensured the actual silent state of the cluster, because, as 
mentioned, SNA01166 might not be involed in the biosynthetic pathway of the bacteriocin. 
SNA01164, as encoding for a protein with a TIGR04222 domain, typical in proteins whose C-
terminal sequence resembles ribosomal natural product precursors, should be the best 
candidate. Additionally, since S. natalensis ΔpimM [pIBSNA01173] extract did not unveil the 
pimaricin peak at the 304 nm HPLC chromatogram while S. natalensis [pIBSNA01173] 
presented higher pimaricin specific production levels than the control, pimS1 expression 
should be analysed in both strains. This way, it is not regu. 
If the activation of either S1C5 or S5C20 is not achieved, one other putative positive CSR 
should be selected to be overexpressed together with a putative negative CSR to be silenced. 
According to the obtained transcription data together with the in silico analysis, SNA01250 
from S1C5 and SNA06239 and SNA06243 from S5C20 are the genes that could be selected to 
be overexpressed. SNA01232, SNA01254, SNA01256 and SNA01258 from S1C5 and SNA06240 
and SNA06245 from S5C20, due to their high transcription levels and in silico identification as 
putative negative CSRs encoding genes, could be selected to be silenced. It should be noted 
that the overexpression and the silencing of the proposed genes can be done separately or 
simultaneously, thereby increasing the chances to be succeed. In fact, the silencing of such 
genes may also be done in the strains overexpressing SNA01173, SNA01239 or SNA06246, 
already developed and available. 
In turn, in case S1C4 is actually silent (as it does not include other putative CSR rather 
than SNA01173) and/or all the last gene cluster activation strategies failed to succeed, other 
approaches could be applied, namely the heterologous expression. S. coelicolor M146, a 
derivative strain of S. coelicolor M145, is a potential candidate for this approach. It lacks 
potentially competitive sinks of carbon and nitrogen, and, in order to provide a host devoid of 
antibiotic activity, its four endogenous secondary metabolite gene clusters responsible for 
actinorhodin, prodiginine, CPK and CDA biosynthesis are deleted. It also holds point mutations 
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into rpoB and rpsL to pleiotropically increase the level of secondary metabolite production 
(Gomez-Escribano and Bibb, 2011). 
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Table A1 – BLASTp analysis of S1C1 encoding genes 
Gene Best hit description 
E-value  
(% Identity) 
SNA00084 Hypothetical protein (Streptomyces sp. BoleA5) 1e-41 (39%) 
SNA00085 Hypothetical protein (Streptomyces sp. HmicA12) 2e-10 (44%) 
SNA00086 Hypothetical protein (Streptomyces sp. HmicA12) 7e-81 (56%) 
SNA00087 Hypothetical protein (Streptomyces sp. MspMP-M5) 1e-169 (77%) 
SNA00088 LysR family transcriptional regulator (Streptomyces albulus) 5e-150 (81%) 
SNA00089 Hypothetical protein (Streptomyces sp. MspMP-M5) 5e-143 (80%) 
SNA00090 Uncharacterized protein UHOR_00132 (Ustilago hordei) 0.93 (50%) 
SNA00091 Hypothetical protein (Streptomyces sp. MspMP-M5) 1e-34(93%) 
SNA00092 Glyoxalase (Streptomyces venezuelae) 1e-65 (85%) 
SNA00094 
SAM-dependent methlyltransferase (Streptomyces sp. NRRL S-
237) 
0.0 (88%) 
SNA00095 
Terpene synthase metal-binding domain-containing protein 
(Streptomyces violaceusniger Tu 4113) 
0.0 (82%) 
SNA00096 
Crp/Fnr family transcriptional regulator (Streptomyces sp. NRRL 
S-237) 
1e-21 (73%) 
SNA00097 Hypothetical protein (Streptomyces auratus) 3e-36 (83%) 
SNA00098 Hypothetical protein (Streptomyces auratus) 1e-124 (93%) 
SNA00100 AMP-dependent synthetase (Streptomyces filamentosus) 2e-167 (56%) 
SNA00101 
Phosphopantetheine-binding protein (Streptomyces 
roseochromogenes) 
1e-21 (60%) 
SNA00102 Decarboxylase (Actinoplanes sp. SE50/110) 4e-129 (54%) 
SNA00103 Hypothetical protein (Streptomyces roseochromogenesi) 2e-10 (29%) 
SNA00104 Hypothetical protein (Streptomyces albulus) 1e-19 (38%) 
SNA00105 
Hypothetical protein BMG523Draft_00765 (Frankia sp. 
BMG5.23) 
3e-75 (63%) 
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Table A2 – BLASTp analysis of S1C2 encoding genes 
Gene Best hit description 
E-value  
(% Identity) 
SNA00374 Acyl-CoA dehydrogenase (Streptomyces sp. FxanaC1)  0.0 (85%) 
SNA00375 Histidine kinase (Streptomyces auratus) 3e-120 (85%) 
SNA00376 ATP-binding protein (Streptomyces auratus) 2e-120 (80%) 
SNA00377 Hypothetical protein (Streptomyces sp. FxanaC1) 8e-75(90%) 
SNA00378 Dynein regulation protein LC7 (Streptomyces sp. FxanaC1) 9e-77 (75%) 
SNA00379 Sensor histidine kinase, partial (Streptomyces rimosus) 2e-154 (69%) 
SNA00381 Hypothetical protein (Streptomyces aurantiacus) 5e-89 (69%) 
SNA00382 Hypothetical protein (Streptomyces aurantiacus) 4e-13 (61%) 
SNA00383 Metallo-beta-lactamase (Streptomyces prunicolor) 0.0 (69%) 
SNA00384 Hypothetical protein (Streptomyces sp. MspMP-M5) 0.0 (79%) 
SNA00385 Hypothetical protein (Streptomyces sp. MspMP-M5) 0.0 (74%) 
SNA00386 Hypothetical protein (Streptomyces thermolilacinus) 0.0 (58%) 
SNA00387 Hypothetical protein (Streptomyces purpureus) 6e-100 (50%) 
SNA00388 Hypothetical protein (Streptomyces sp. MspMP-M5) 1e-124 (66%) 
SNA00389 Endonuclease (Streptomyces violaceusniger) 4e-143 (73%) 
SNA00390 C14 family peptidase (Streptomyces sp. SS) 9e-130 (65%) 
SNA00391 Hypothetical protein (Streptomyces sp. FxanaC1) 2e-22 (73%) 
SNA00392 Secreted protein (Streptomyces auratus AGR0001) 9e-129 (56%) 
SNA00393 O-methyltransferase family 2 (Streptomyces albulus) 0.0 (82%) 
SNA00394 
Polyketide cyclase WhiE VII (Streptomyces venezuelae ATCC 
10712) 
4e-58 (81%) 
SNA00395 Aromatase WhiE VI (Streptomyces albulus) 7e-89 (78%) 
SNA00396 Acyl carrier protein (Streptomyces auratus AGR0001) 5e-35 (73%) 
SNA00397 
Polyketide chain length factor WhiE-CLF (Streptomyces 
gancidicus) 
0.0 (78%) 
SNA00398 
Polyketide beta-ketoacyl synthase WhiE-KS (Streptomyces 
albulus) 
0.0 (89%) 
SNA00399 Polyketide cyclase WhiE II (Streptomyces gancidicus BKS 13-15) 8e-67 (72%) 
SNA00400 SchA/CurD domain-containing protein (Streptomyces albulus) 0.0 (78%) 
SNA00401 Monooxygenase FAD-binding protein (Streptomyces albulus) 0.0 (79%) 
SNA00402 Hypothetical protein (Streptomyces sp. FxanaC1) 7e-151 (71%) 
SNA00403 AbaA-like protein (Streptomyces albulus) 1e-52 (93%) 
SNA00404 
DNA-binding protein (XRE-family like protein) (Streptomyces sp. 
FxanaC1) 
0.0 (93%) 
SNA00405 ATP-binding protein (Streptomyces albulus) 7e-67 (84%) 
SNA00406 SGNH hydrolase (Streptomyces auratus) 6e-174 (91%) 
SNA00407 
Protein tyrosine/serine phosphatase (Streptomyces albulus CCRC 
11814) 
2e-159 (85%) 
SNA00408 
aromatic ring-opening dioxygenase LigA (Streptomyces 
bingchenggensis) 
8e-131 (59%) 
SNA00409 Aminotransferase (Streptomyces rimosus) 0.0 (89%) 
SNA00410 
1-deoxy-D-xylulose-5-phosphate synthase (Streptomyces 
auratus) 
0.0 (88%) 
SNA00411 Radical SAM protein (Streptomyces auratus) 0.0 (96%) 
SNA00412 Hypothetical protein (Streptomyces rimosus) 8e-99 (79%) 
SNA00413 Squalene-hopene cyclase (Streptomyces sp. FxanaC1) 0.0 (84%) 
SNA00414 Dimethylallyltranstransferase (Streptomyces sp. MspMP-M5) 0.0 (94%) 
SNA00415 
Squalene/phytoene dehydrogenase (Streptomyces auratus 
AGR0001) 
0.0 (85%) 
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Table A2 – BLASTp analysis of S1C2 encoding genes (continuation) 
Gene Best hit description 
E-value  
(% Identity) 
SNA00416 Phytoene synthase (Streptomyces sp. FxanaC1) 0.0 (91%) 
SNA00417 Squalene synthase (Streptomyces sp. FxanaC1) 6e-175 (91%) 
SNA00418 Hypothetical protein (Candidatus Latescibacter anaerobius) 2.0 (47%) 
SNA00419 
Techoic acid ABC transporter ATP-binding protein (Streptomyces 
sp. MspMP-M5) 
0.0 (93%) 
SNA00420 ABC transporter (Streptomyces auratus) 0.0 (90%) 
SNA00421 Glycosyl transferase (Streptomyces prunicolor) 5e-177 (86%) 
SNA00422 Transferase (Streptomyces sp. FxanaC1) 1e-141 (90%) 
SNA00423 Dehydrogenase (Streptomyces auratus) 0.0 (95%) 
SNA00424 
Putative mannose-1-phosphate guanylyltransferase 1 
(Streptomyces aurantiacus) 
5e-171 (98%) 
SNA00425 Transferase (Streptomyces sp. FxanaC1) 0.0 (86%) 
SNA00426 Multidrug resistance-associated protein 6 (Canis lupus familiaris) 6.2 (38%) 
SNA00427 Isopentenyl-diphosphate delta-isomerase (Streptomyces albulus) 2e-126 (92%) 
SNA00428 Regulatory protein (Streptomyces auratus) 9e-72 (86%) 
SNA00429 Hypothetical protein CARUB_v10012271mg (Capsella rubella) 1.6 (46%) 
SNA00430 Enoyl-CoA hydratase (Streptomyces sp. FxanaC1) 0.0 (89%) 
SNA00431 
Heme ABC transporter ATP-binding protein (Streptomyces sp. 
FxanaC1) 
1e-147 (92%) 
SNA00432 Glutamine amidotransferase (Streptomyces auratus) 2e-124 (84%) 
SNA00433 AraC family transcriptional regulator (Streptomyces sp. FxanaC1) 7e-179 (85%) 
SNA00434 Hypothetical protein (Streptomyces sp. FxanaC1) 6e-164 (83%) 
SNA00435 RNA-binding protein (Streptomyces sp. FxanaC1) 0.0 (92%) 
SNA00436 Hypothetical protein (Streptomyces sp. FxanaC1) 0.0 (87%) 
SNA00437 ATPase AAA (Streptomyces niveus) 0.0 (69%) 
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Table A3 – BLASTp analysis of S1C3 encoding genes 
Gene Best hit description 
E-value  
(% Identity) 
SNA00822 Transposase (Mycobacterium avium subsp. hominissuis TH135) 6e-136 (51%) 
SNA00823 Uracil-DNA glycosylase (Rhizobium grahamiiI) 6.9 (32%) 
SNA00824 Hypothetical protein (Streptomyces cattleyaI) 0.0 (66%) 
SNA00825 Hypothetical protein (Streptomyces canus) 0.015 (77%) 
SNA00826 IS1647-like transposase (Streptomyces sp. GBA 94-10) 9e-71 (85%) 
SNA00827 Glyoxalase (Streptomyces auratus) 1e-141 (77%) 
SNA00828 Hypothetical protein (Streptomyces auratus) 0.0 (84%) 
SNA00829 Hypothetical protein (Streptomyces auratus) 3e-64 (73%) 
SNA00830 Regulator (Streptomyces filamentosus) 7e-165 (48%) 
SNA00831 SAM-dependent methyltransferase (Streptomyces auratus 1e-126 (70%) 
SNA00832 Hypothetical protein (Streptomyces auratus) 1e-178 (75%) 
SNA00833 Ribonuclease BN (Streptomyces sp. FxanaC1) 2e-158 (84%) 
SNA00834 
Pterin-4-alpha-carbinolamine dehydratase (Streptomyces sp. 
FxanaC1) 
2e-53 (81%) 
SNA00835 XRE family transcriptional regulator (Streptomyces sp. FxanaC1) 3e-161 (88%) 
SNA00836 Isomerase (Streptomyces sp. PsTaAH-124) 1e-30 (74%) 
SNA00837 Hypothetical protein (Streptomyces sp. CNT372) 1e-53 (77%) 
SNA00838 Transporter (Streptomyces auratus) 0.0 (90%) 
SNA00839 Hypothetical protein (Streptomyces sp. FxanaC1 0.0 (78%) 
SNA00840 Aminopeptidase (Streptomyces auratus) 0.0 (77%) 
SNA00841 Type III polyketide synthase RppA (Streptomyces albulus) 0.0 (89%) 
SNA00842 Hypothetical protein KGM_06486 (Danaus plexippus) 1.5 (28%) 
SNA00843 Cytochrome P450 (Streptomyces albulus) 0.0 (84%) 
SNA00844 Phosphoesterase (Streptomyces albulus) 0.0 (78%) 
SNA00845 UbiE family methyltransferase (Streptomyces auratus) 2e-170 (87%) 
SNA00846 Glyoxalase (Streptomyces sp. MspMP-M5) 1e-71 (96%) 
SNA00847 Alcohol dehydrogenase (Streptomyces auratus) 0.0 (83%) 
SNA00848 Hypothetical protein (Streptomyces sp. FxanaC1) 0.0 (82%) 
SNA00849 Acetyltransferase (Streptomyces sp. FxanaC1) 1e-94 (76%) 
SNA00850 Transposase (Streptomyces fradiae) 0.0 (77%) 
SNA00851 TetR family transcriptional regulator (Streptomyces sp. FxanaC1) 3e-92 (77%) 
SNA00852 Hypothetical protein (Streptomyces sp. FxanaC1) 4e-137 (70%) 
SNA00853 Hypothetical protein (Streptomyces sp. FxanaC1) 4e-137 (70%) 
SNA00854 Ferredoxin (Streptomyces tubercidicus) 1e-29 (84%) 
SNA00855 S15 family peptidase (Streptomyces albulus) 0.0 (79%) 
SNA00856 Acyl-peptide hydrolase (Streptomyces sp. FxanaC1) 0.0 (84%) 
SNA00858 Hypothetical protein (Streptomyces albulus) 0.0 (86%) 
SNA00859 
Peptide ABC transporter substrate-binding protein (Streptomyces 
sp. FxanaC1) 
0.0 (94%) 
  
Page 97 
Table A4 – BLASTp analysis of S1C4 encoding genes 
Gene Best hit description 
E-value  
(% Identity) 
SNA01156 ATPase (Streptomyces sp. FxanaC1) 0.0 (90%) 
SNA01157 Predicted protein (Streptomyces iranensis) 2e-19 (95%) 
SNA01158 ABC transporter (Streptomyces rimosus) 4e-77 (72%) 
SNA01159 ABC transporter (Streptomyces sp. FxanaC1) 3e-151 (76%) 
SNA01160 Peptidyl-tRNA hydrolase (Streptomyces auratus) 3e-147 (77%) 
SNA01161 Hypothetical protein (Streptomyces sp. FxanaC1) 2e-125 (89%) 
SNA01162 Endonuclease (Streptomyces rapamycinicus) 3e-166 (89%) 
SNA01163 Endonuclease (Streptomyces purpureus) 7e-52 (65%) 
SNA01164 Hypothetical protein (Streptomyces albulus) 6e-68 (50%) 
SNA01165 Hypothetical protein (Streptomyces sp. MspMP-M5) 3e-76 (60%) 
SNA01166 Tripeptidyl aminopeptidase (Streptomyces auratus) 0.0 (71%) 
SNA01167 Hypothetical protein (Streptomyces sp. FxanaC1) 8e-68 (93%) 
SNA01168 Protoporphyrinogen oxidase (Streptomyces auratus) 0.0 (77%) 
SNA01169 Acetyl-CoA acetyltransferase (Streptomyces sp. FxanaC1) 0.0 (94%) 
SNA01170 Flavoprotein oxidoreductase (Streptomyces sp. FxanaC1) 0.0 (94%) 
SNA01171 Uroporphyrinogen decarboxylase (Streptomyces albulus) 0.0 (91%) 
SNA01172 Hypothetical protein (Streptomyces auratus) 2e-123 (85%) 
SNA01173 LuxR family transcriptional regulator (Streptomyces albulus PD-1) 3e-134 (100%) 
SNA01174 Hypothetical protein (Streptomyces sp. W007) 3e-13 (46%) 
SNA01175 Hypothetical protein (Streptomyces aurantiacus) 1e-22 (56%) 
SNA01176 3'-5' exonuclease (Streptomyces sp. FxanaC1) 0.0 (92%) 
SNA01177 Acetyl-CoA acetyltransferase (Streptomyces avermitilis) 0.0 (97%) 
SNA01178 3-hydroxyacyl-CoA dehydrogenase (Streptomyces auratus) 0.0 (95%) 
SNA01179 Hypothetical protein (Streptomyces auratus) 4e-59 (84%) 
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Table A5 – BLASTp analysis of S1C5 encoding genes 
Gene Best hit description 
E-value 
(% Identity) 
SNA01188 
ABC transporter substrate-binding protein (Streptomyces sp. 
Fxanac1) 
0.0 (89%) 
SNA01189 Apha-1 2-mannosidase (Streptomyces sp. FxanaC1) 0.0 (78%) 
SNA01190 Hypothetical protein cf54_33035 (Streptomyces sp. Tu 6176) 3e-39 (57%) 
SNA01191 Aconitate hydratase (Streptomyces auratus) 0.0 (96%) 
SNA01192 Hypothetical protein (Streptomyces auratus) 2e-11 (48%) 
SNA01193 RNA polymerase sigma 70 (Streptomyces sp. FxanaC1) 1e-144 (75%) 
SNA01194 
UDP-n-acetylglucosamine 1-carboxyvinyltransferase 
(Streptomyces sp. FxanaC1) 
0.0 (96%) 
SNA01195 Integrase (Streptomyces sp.) 0.0 (86%) 
SNA01196 Endonuclease DDE (Streptomyces albulus PD-1) 0.0 (84%) 
SNA01197 Acetyltransferase (Streptomyces auratus) 2e-113 (87%) 
SNA01198 Hypothetical protein (Streptomyces auratus) 0.0 (86%) 
SNA01199 ATP-binding protein (Streptomyces auratus) 6e-53 (73%) 
SNA01200 Nudix hydrolase (Streptomyces auratus) 2e-64 (80%) 
SNA01201 Aminoglycoside phosphotransferase (Streptomyces auratus) 2e-29 (73%) 
SNA01202 Amidinotransferase (Streptomyces sp. C) 3e-145 (79%) 
SNA01203 
Mitogen-activated protein kinase kinase kinase kinase 5-like 
(Ailuropoda melanoleuca) 
2.2 (52%) 
SNA01204 Hypothetical protein (Streptomyces scabrisporus) 1e-74 (72%) 
SNA01205 Antibiotic biosynthesis protein (Frankia alni) 1e-72 (62%) 
SNA01207 Transposase (kitasatospora setae) 2e-104 (49%) 
SNA01208 
Sodium/hydrogen exchanger (Micromonospora aurantiaca ATCC 
27029) 
8e-100 (55%) 
SNA01209 
Alpha/beta hydrolase fold protein (Catenulispora acidiphila DSM 
44928) 
3e-100 (49%) 
SNA01210 Chlorinating enzyme (Catenulispora acidiphila DSM 44928) 2e-159 (71%) 
SNA01211 
Putative non-ribosomal peptide synthetase (Actinokineospora 
sp. EG49) 
8e-07 (38%) 
SNA01212 
Amino acid adenylation domain-containing protein 
(Catenulispora acidiphila DSM 44928) 
3e-163 (53%) 
SNA01213 Thioesterase (Streptomyces viridosporus) 4e-77 (55%) 
SNA01214 Peptidase s9 (Streptomyces purpureus) 0.0 (64%) 
SNA01215 Cytochrome p450 monooxygenase (Nocardiopsis sp. FU40) 9e-146 (54%) 
SNA01216 Ferredoxin (Nocardia brasiliensis ATCC 700358) 2e-12 (64%) 
SNA01217 Cytochrome P450 hydroxylase (Streptomyces albulus) 4e-174 (67%) 
SNA01218 ABC transporter (Streptomyces violaceusniger Tu 4113) 5e-100 (57%) 
SNA01219 ABC transporter (Saccharomonospora cyanea) 4e-147 (69%) 
SNA01220 Hypothetical protein (Amycolatopsis nigrescens) 2e-82 (48%) 
SNA01221 hypothetical protein (Streptomyces natalensis) 7e-119 (100%) 
SNA01222 Acyltransferase 3 (Frankia sp. EAN1pec) 5e-67 (46%) 
SNA01223 Antibiotic synthesis protein mbth (Smaragdicoccus niigatensis) 4e-35 (76%) 
SNA01224 
Putative l-ornithine 5-monooxygenase (Streptomyces 
aurantiacus) 
0.0 (61%) 
SNA01225 
Putative nonribosomal peptide synthetase (Streptomyces 
griseovariabilis subsp. bandungensis) 
0.0 (50%) 
 
Page 99 
Table A5 – BLASTp analysis of S1C5 encoding genes (continuation) 
Gene Best hit description 
E-value  
(% Identity) 
SNA01226 Non-ribosomal peptide synthetase (Rhodococcus hoagie) 0.0 (43%) 
SNA01227 Pyruvate carboxyltransferase (Nocardia brasiliensis ATCC) 3e-164 (67%) 
SNA01228 
Isopropylmalate isomerase large subunit (Nocardia brasiliensis 
atcc 700358) 
0.0 (74%) 
SNA01229 
Isopropylmalate isomerase small subunit (Nocardia brasiliensis 
ATCC 700358) 
9e-87 (68%) 
SNA01230 Aminotransferase class I/II (Nocardia brasiliensis) 3e-160 (63%) 
SNA01231 Cytochrome P450 (Saccharopolyspora spinosa) 0.0 (65%) 
SNA01232 TetR family transcriptional regulator (Streptomyces albulus) 4e-92 (59%) 
SNA01233 Hypothetical protein (Acinetobacter baumannii) 8.6 (44%) 
SNA01234 
Hypothetical protein rw1_060_00180 (Rhodococcus 
wratislaviensis NBRC 100605) 
2e-87 (51%) 
SNA01235 Hypothetical protein (Streptomyces sp. CNT372) 0.0 (59% 
SNA01236 
Methylated-dna- (protein)-cysteine s-methyltransferase dna 
binding protein (Streptomyces sp. S4) 
0.0 (72%) 
SNA01237 Putative transposase (Streptomyces himastatinicus) 3e-171 (74%) 
SNA01238 Phage integrase (Streptomyces scabiei 87.22) 4e-133 (83%) 
SNA01239 MerR family transcriptional regulator (Streptomyces avermitilis) 4e-161 (82%) 
SNA01240 Transposase, partial (Streptomyces scabiei 87.22) 0.0 (87%) 
SNA01241 Hypothetical protein (Streptomyces sp. MspMP-M5) 6e-111 (94%) 
SNA01242 6-phosphogluconate dehydrogenase (Streptomyces sp. CNB091) 1e-64 (54%) 
SNA01243 
O-methyltransferase family protein (Nostoc punctiforme PCC 
73102) 
9e-64 (33%) 
SNA01244 
Biopterin-dependent aromatic amino acid hydroxylase family 
protein (Gordonia sp. NB4-1Y) 
1e-57 (45%) 
SNA01245 
Pyridoxal-dependent amino acid decarboxylase (Amycolatopsis 
nigrescens) 
0.0 (71%) 
SNA01246 L-amino-acid oxidase (Saccharothrix espanaensis DSM 44229) 6e-57 (34%) 
SNA01247 Methylase (Streptomyces clavuligerus) 2e-93 (50%) 
SNA01248 2'-carbamoyl transferase (Streptomyces sp. SANK 62799) 0.0 (54%) 
SNA01249 Alpha-parvin (Chlorocebus sabaeus) 6.8 (47%) 
SNA01250 
DeoR family transcriptional regulator (Streptomyces clavuligerus 
ATCC 27064) 
1e-144 (80%) 
SNA01251 Hydroxylase (Streptomyces auratus) 1e-134 (74%) 
SNA01252 Acyl-coa dehydrogenase (Streptomyces sp. FxanaC1) 0.0 (91%) 
SNA01253 AMP-dependent synthetase (Streptomyces sp. FxanaC1) 0.0 (85%) 
SNA01254 PaaX family transcripitonal regulator (Streptomyces sp. FxanaC1) 2e-159 (86%) 
SNA01255 Had-superfamily hydrolase (Streptomyces auratus) 2e-152 (92%) 
SNA01256 Transcriptional regulator, TetR family (Streptomyces ipomoeae) 1e-18 (33%) 
SNA01257 Dehydrogenase (Streptomyces albulus) 2e-160 (74%) 
SNA01258 KsbA (TetR family) Streptomyces auratus) 9e-128 (89%) 
SNA01259 Enoyl-coa hydratase (Streptomyces rimosus) 2e-158 (89%) 
SNA01260 Salicylyl-coa 5-hydroxylase (Streptomyces sp. FxanaC1) 0.0 (85%) 
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Table A6 – BLASTp analysis of S5C20 encoding genes 
Gene Best hit description 
E-value  
(% Identity) 
SNA06231 PadR family transcriptional regulator (Streptomyces albulus) 8e-111 (82%) 
SNA06232 Hypothetical protein (Streptomyces sp. FxanaC1) 0.0 (85%) 
SNA06233 Hypothetical protein (Streptomyces sp. TOR3209) 1e-99 (78%) 
SNA06234 Hypothetical protein (Streptomyces hygroscopicus) 4e-141 (91%) 
SNA06235 Hypothetical protein (Longispora albida) 2e-23 (43%) 
SNA06236 Hypothetical protein (Streptomyces bingchenggensis) 1e-98 (56%) 
SNA06237 Hypothetical protein (Streptomyces himastatinicus) 0.0 (73%) 
SNA06239 
GntR family transcriptional regulator (Streptosporangium roseum 
DSM 43021) 
3e-146 (69%) 
SNA06240 LysR family transcriptional regulator (Thermobifida fusca YX) 4e-59 (45%) 
SNA06241 Aminotransferase (Streptomyces sp. CNT302) 0.0 (76%) 
SNA06242 Lysine 2,3-aminomutase (Streptomyces sp. AA4) 0.0 (65%) 
SNA06243 Transcriptional regulator, AsnC family (Kutzneria sp. 744) 5e-48 (55%) 
SNA06244 Integrase (Streptomyces auratus) 1e-10 (38%) 
SNA06245 AfsR family transcriptional regulator (Streptomyces griseus) 1e-170 (53%) 
SNA06246 
LuxR family transcriptional regulator (Streptosporangium 
roseum) 
4e-38 (44%) 
SNA06247 Hypothetical protein (Amycolatopsis nigrescens) 2e-43 (63%) 
SNA06248 Hypothetical protein (Streptomyces flavochromogenes) 3e-15 (58%) 
SNA06249 Hypothetical protein (Nocardiopsis chromatogenes) 1e-49 (50%) 
SNA06250 
3-oxoacyl- (acyl-carrier-protein) synthase III (Bacillus 
thuringiensis serovar finitimus YBT-020) 
1e-80 (31%) 
SNA06251 Hypothetical protein (Nocardiopsis prasina) 0.073 (28%) 
SNA06252 Hypothetical protein (Nocardiopsis chromatogenes) 2e-97 (30%) 
SNA06253 3-ketoacyl-ACP reductase (Clostridiales) 1e-20 (23%) 
SNA06254 
Malonyl-CoA-[acyl-carrier-protein] transacylase (Desmospora sp. 
8437) 
3e-23 (78%) 
SNA06255 Malonyl CoA-ACP transacylase (Wolbachia pipientis) 0.009 (24%) 
SNA06256 Glycine amidinotransferase (Streptomyces sp. CNB091) 0.0 (45%) 
SNA06257 Mixed NRPS PKS (Streptomyces sp. K01-0509) 0.0 (53%) 
SNA06258 Thioesterase (Mycobacterium) 1e-54 (37%) 
SNA06259 Hypothetical protein (Salinispora pacifica) 2e-19 (40%) 
SNA06260 Flavoprotein (Patulibacter americanus) 2e-27 (37%) 
SNA06261 Serine/threonine protein kinase (Kutzneria albida DSM 43870) 4e-122 (49%) 
SNA06262 Hypothetical protein (Salinispora arenicola) 2e-33 (40%) 
SNA06264 
Hypothetical protein DOTSEDRAFT_164870 (Dothistroma 
septosporum NZE10) 
6.3 (49%) 
SNA06265 Hypothetical protein (Streptomyces sp. FxanaC1) 1e-71 (78%) 
SNA06268 Deoxycytidine triphosphate deaminase (Streptomyces albulus) 2e-130 (95%) 
SNA06269 Phosphoribosyltransferase (Streptomyces sp. MspMP-M5) 2e-110 (96%) 
SNA06270 Ricin B lectin (Streptomyces sp. FxanaC1) 0.0 (86%) 
SNA06271 Membrane protein (Streptomyces sp. MspMP-M5) 4e-149 (77%) 
SNA06272 Ribonuclease HI (Streptomyces sp. FxanaC1) 1e-125 (81%) 
SNA06273 
Drug:H+ antiporter-2 (14 Spanner) (DHA2) family drug resistance 
MFS transporter (Streptomyces sp. HGB0020) 
0.0 (75%) 
SNA06274 
TetR family transcriptional regulator (Streptomyces sp. 
AW19M42) 
2e-47 (52%) 
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Table A6 – BLASTp analysis of S5C20 encoding genes (continuation) 
Gene Best hit description 
E-value  
(% Identity) 
SNA06275 Ribonuclease HI (Streptomyces sp. FxanaC1) 1e-125 (81%) 
SNA06276 Fe-S oxidoreductase (Streptomyces sp. FxanaC1) 0.0 (94%) 
SNA06277 
Molecular chaperone DnaK (Streptomyces griseus subsp. griseus 
NBRC 13350) 
0.0 (92%) 
SNA06278 Acetyltransferase GCN5 (Streptomyces auratus) 1e-64 (78%) 
SNA06279 
Drug:H+ antiporter-2 (14 Spanner) (DHA2) family drug resistance 
MFS transporter (Streptomyces sp. HGB0020) 
0.0 (75%) 
SNA06280 Molecular chaperone DnaK (Streptomyces sp. AW19M42) 0.0 (92%) 
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Table A7 – Typical roles of the different families of regulators identified in the selected clusters  
Regulator Role (Reference) Genes (cluster) 
AbaA-family 
Unknown (Fernández-Moreno et al., 
1992) 
SNA00403 (S1C2) 
AfsR-family Positive (Horinouchi et al., 1990) SNA06245 (S5C20) 
AraC-family 
Positive (Soisson et al., 1997, Martin 
and Rosner, 2001) 
SNA00399 (S1C2) 
 SNA00433 (S1C2) 
AsnC-family 
Negative (Pérez-Rueda and Collado-
Vides, 2001) 
SNA06243 (S5C20) 
CRP/FNR-family 
Positive (Kolb et al., 1993, Korner et 
al., 2003) 
SNA00096 (S1C1) 
DeoR-family Negative (Skerlová et al., 2014) SNA01250 (S1C5) 
GntR-family 
Negative (Hillerich and Westpheling, 
2006) 
SNA06239 (S5C20) 
LuxR-family Positive (Chen and Xie, 2011) 
SNA01173 (S1C4) 
SNA06246 (S5C20) 
LysR family Positive (Schell, 1993) 
SNA00088 (S1C1) 
SNA06240 (S5C20) 
MerR-family Positive (Brown et al., 2003) SNA01239 (S1C5) 
PaaX family Negative (Niewerth et al., 2013) SNA01254 (S1C5) 
PadR-family 
Negative (Gury et al., 2004, 
Fibriansah et al., 2012) 
SNA06231 (S5C20) 
Regulator Unknown 
SNA00428 (S1C2) 
SNA00830 (S1C3) 
SNA06248 (S5C20) 
RNA polymerase 
sigma factor 
Positive (Gruber and Gross, 2003) SNA01193 (S1C5) 
Serine/threonine 
protein kinase 
Unknown SNA06261 (S5C20) 
TetR-family Negative (Ramos et al., 2005) 
SNA00851 (S1C3) 
SNA01232 (S1C5) 
SNA01256 (S1C5) 
SNA01258 (S1C5) 
SNA06274 (S5C20) 
XRE-family 
Negative (Durante-Rodriguez et al., 
2010) 
SNA00405 (S1C2) 
SNA00835 (S1C3) 
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Figure A1 – HPLC diode array analysis of S. natalenis wild-type culture broth extract. The wavelength is expressed 
(nm) as a function of retention time (min). The red box marks the area that varies the most among all 
strains extracts. 
 
 
Figure A2 – HPLC diode array analysis of S. natalenis [pIB139] culture broth extract. The wavelength is expressed 
(nm) as a function of retention time (min). The red box marks the area that varies the most among all 
strains extracts. 
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Figure A3 – HPLC diode array analysis of S. natalenis [pIBSNA06246] culture broth extract. The wavelength is 
expressed (nm) as a function of retention time (min). The red box marks the area that varies the most 
among all strains extracts. 
 
 
Figure A4 – HPLC diode array analysis of S. natalenis [pIBSNA01239] culture broth extract. The wavelength is 
expressed (nm) as a function of retention time (min). The red box marks the area that varies the most 
among all strains extracts. 
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Figure A5 – HPLC diode array analysis of S. natalenis [pIBSNA01173] culture broth extract. The wavelength is 
expressed (nm) as a function of retention time (min). The red box marks the area that varies the most 
among all strains extracts. 
 
 
Figure A6 – HPLC diode array analysis of S. natalenis ΔpimM culture broth extract. The wavelength is expressed 
(nm) as a function of retention time (min). The red box marks the area that varies the most among all 
strains extracts. 
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Figure A7 – HPLC diode array analysis of S. natalenis ΔpimM [pIB139] culture broth extract. The wavelength is 
expressed (nm) as a function of retention time (min). The red box marks the area that varies the most 
among all strains extracts. 
 
 
Figure A8 – HPLC diode array analysis of S. natalenis ΔpimM [pIBSNA06246] culture broth extract. The wavelength is 
expressed (nm) as a function of retention time (min). The red box marks the area that varies the most 
among all strains extracts. 
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Figure A9 – HPLC diode array analysis of S. natalenis ΔpimM [pIBSNA01239] culture broth extract. The wavelength is 
expressed (nm) as a function of retention time (min). The red box marks the area that varies the most 
among all strains extracts. 
 
 
Figure A10 – HPLC diode array analysis of S. natalenis ΔpimM [pIBSNA01173] culture broth extract. The wavelength 
is expressed (nm) as a function of retention time (min). The red box marks the area that varies the 
most among all strains extracts. 
